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Summary 
 
Artemisia afra (A. afra) is traditionally used for a variety of ailments and contain flavonoids e.g. 
luteolin which may contribute to some of its activity. It is generally administered as a tea or 
decoction, and such liquid dosage forms present challenges as far as long term storage and 
stability are concerned, as well as sub-optimal oral bioavailability of actives they contain. Freeze 
dried aqueous extracts (FDAE) can alleviate such problems but may be hygroscopic and 
unstable. The use of modified forms of FDAE can counter the problem of hygroscopicity (e.g. 
use of alginate) and alleviate the issue of sub-optimal bioavailability of plant actives (e.g. 
polymethylmethacrylate). 
 
The objectives of this study, were to: (1) prepare the freeze dried aqueous extract (FDAE) and 
modified forms, which include alginate-extract beads (alginate-FDAE) and 
polymethylmethacrylate coated alginate matrix  beads of herbal extract (PMMA-alginate-FDAE) 
of the FDAE of A. afra, (2) determine and compare the pharmaceutical characteristics of the 
above mentioned preparations of A. afra,(3) quantify and compare the total flavonoid and 
specifically luteolin levels of the different forms of A. afra,(4) evaluate and compare the release 
characteristics of FDAE of A. afra  from the alginate-FDAE and PMMA-alginate-FDAE beads 
in gastrointestinal fluids and (5) determine the intestinal permeability of luteolin contained in 
selected modified Artemisia afra extract preparations. It was hypothesized that making the 
alginate beads and the polymethylmethacrylate coated alginate beads would make the FDAE less 
hygroscopic with a lower moisture content, that the rate of release of luteolin from A. afra FDAE 
into gastrointestinal fluids would be faster than from the modified forms, and that the effective 
gastrointestinal permeability of luteolin in the alginate-FDAE and PMMA-alginate-FDAE beads 
of A. afra is equal to that in FDAE. 
To realize these objectives, the FDAE was prepared by freeze drying the aqueous extract of the 
A. afra dried leaves, alginate-FDAE prepared by dispersing FDAE into 4% sodium alginate 
solution, then adding the resulting stock solution into a 2% calcium chloride solution and drying 
resulting beads and PMMA-alginate-FDAE prepared by a modified water-in-oil-in-water 
emulsion solvent evaporation method using water as an internal aqueous phase. Using 
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pharmacopoeial methods and methods adapted from other workers the organoleptic and 
pharmaceutical characteristics were determined to compare the pharmaceutical quality of these 
preparations of A. afra. To identify and determine the levels of luteolin in the plant preparations, 
a validated HPLC assay was developed. Finally, the in situ perfused rat intestine model was used 
to determine the in vitro bioavailability, i.e. gastrointestinal permeability, of luteolin from 
solutions containing luteolin in pure form, FDAE, alginate-FDAE and PMMA-alginate-FDAE.  
The A. afra forms were obtained in moderate to good yields and FDAE was brown and 
hygroscopic in nature, the alginate beads dark brown free flowing and spherical in shape and the 
PMMA-alginate beads light brown in colour with rough edges. The A. afra plant forms on 
average contained 0.185 ± 0.24, 0.067 ± 0.014, 0.012 ± 0.071 µg/mg of free luteolin (n=3) in 
FDAE, alginate-FDAE and PMMA-alginate-FDAE respectively and 0.235 ± 0.026, 0.079 ± 
0.093, 0.058 ± 0.082 µg/mg of total luteolin (n=3) in FDAE, alginate-FDAE and PMMA-
alginate-FDAE respectively. 
The Plumen values for intestinal uptake of luteolin were significantly higher from solutions of A. 
afra forms than the pure luteolin solution (i.e. Plumen values in the range of 0.02 - 0.035 cm/s for 
all plant forms vs Plumen values in the range of 0.010 - 0.014 cm/s for pure luteolin, t-test p = 
0.0252). The permeability of luteolin in FDAE appeared to be slighter greater than that of the 
modified forms (Plumen values >0.03 cm/s for FDAE and Plumen values <0.03 cm/s for both 
modified forms). 
In summary, the results showed that, the modified A. afra forms; alginate-FDAE and PMMA-
alginate-FDAE were of acceptable pharmaceutical quality with luteolin better taken up in the 
plant forms than in its pure form. The A. afra forms prepared had similar rates of uptake 
(permeability) of free and total luteolin with the rates being highest for the FDAE. Collectively, 
these results indicate that alginate-FDAE and PMMA-alginate-FDAE bead forms should be 
suitable for use in a solid dosage form (e.g. tablet or capsule) of A. afra. 
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Chapter 1 
Introduction 
 
Artemisia afra (A. afra) also known as “Wilde als” or “wormwood” (Roberts, 1990) is one of the 
oldest and best known traditional herbal medicines used in South Africa for the treatment of a 
variety of ailments (Watt and Breyer-Brandwijk, 1962, Van Wyk and Gerike, 2000). The list of 
uses includes treatment of coughs, fever, asthma, malaria and diabetes. A. afra is commonly 
administered as a tea infusion of its leaves and the steam from such infusions may also be 
inhaled for the treatment of headaches and colds (Thring and Weitz, 2006, Hutchings et al., 
1996b). 
The usual dosage preparation of the plant is in the form of a tea or decoction (Roberts, 1990; Van 
Wyk et al., 1997) which involves immersing wet leaves in boiling water. The traditional method 
of preparation has several disadvantages attributed to it. Firstly, the preparations are often left in 
a pot and heated up daily before use leading to a very dark colour of the liquid aqueous extract. 
The dark appearance of the tea is most likely due to more constituents being extracted while the 
water remains in prolonged contact with the plant material. This may result in the alteration of 
many active constituents (especially due to decomposition during the boiling phase) and 
difficulties in ensuring quality control of the herbal ingredients of the final preparation. Also, the 
directions for dosage preparation are often very inaccurate in that quantities are measured as “a 
double handful”, “cup of boiling water” or “quarter cup of leaves” (Roberts, 1990). This may 
cause a lot of variability in different preparations due to the inaccuracy in consistently 
quantifying or measuring either a quarter cup or double handful. Moreover, this may lead to 
variations in dose each time a treatment is prepared which may in turn alter the bioavailability 
and the pharmacokinetics of the active constituents. One solution to address these problems was 
to prepare a freeze-dried aqueous extract powder of the plant which will provide a more uniform 
and constant composition material that is also more amenable for preparation into a solid dosage 
form e.g. tablet or capsule. 
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However, scientific literature and past experience have shown that freeze-dried aqueous 
preparations are also problematic. In particular, they tend to be very sticky and hygroscopic and 
are prone to moisture sorption when exposed to an environment with even moderate humidity. 
The hygroscopic material becomes physically changed with an increase in volume and changes 
in particle size and shape (Egieyeh, 2011). The active compounds in these preparations typically 
have less than satisfactory pharmacokinetic characteristics which include rapid absorption rates, 
quicker metabolism and shorter half-lives. These problems may however also be remedied for 
instance by using appropriate excipients to modify the hygroscopic nature of the extract and 
enhance the in vivo delivery (i.e. bioavailability) and pharmacokinetics of active constituents in 
the active herbal ingredient (AHI) extract. The International Pharmaceutical Excipient Council 
(IPEC) defines an excipient as any substance other than the active drug that is included in the 
manufacturing process. Excipients are commonly used to improve the less than satisfactory 
characteristics e.g. pharmaceutical (i.e. excessive hygroscopicity) or pharmacokinetic (i.e. low 
bioavailability) of active ingredients. Excipients such as alginate and dextran have been used to 
reduce hygroscopicity. For example, Egieyeh showed a 35-75% significant reduction in 
hygroscopicity when a freeze-dried aqueous extract of Artemisia afra was incorporated into a 
matrix of sodium alginate (Egieyeh, 2011). Also, Tong et al., in another experiment incorporated 
dextran into dried aqueous extract of Radix ophiopogonis and observed a reduction of 
hygroscopicity in the extract (Tong et al., 2008). Excipients can also be used to prepare 
controlled or modified release preparations. Tapas et al., (2011) used polymethylmethacrylate 
coated alginate matrix microcapsules to prepare a controlled release dosage form of diclofenac 
sodium which was found to have prolonged release in the intestine with improved absorption. 
This was done using sodium alginate (SAL) as a matrix material in a modified water-in-oil-in-
water emulsion solvent evaporation method. It would be interesting to explore whether alginate-
extract beads (alginate-FDAE) and polymethylmethacrylate coated alginate matrix beads 
(PMMA-alginate-FDAE) could reduce the hygroscopicity of the A. afra freeze dried aqueous 
extract (FDAE), and enhance the bioavailability (permeability and absorption) of the actives 
contained in the extract (AHI). 
Scientifically, it can be assumed that the activities of medicinal plants are due to the active 
ingredients they contain. In most cases, however, the active ingredient(s) actually responsible for 
the therapeutic activities of plants are not known. Very little is known about the chemical 
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constituents responsible for the activity of Artemisia afra. However, several studies have 
revealed that Artemisia afra contains flavonoids e.g. quercetin, acacetin, kaempferol and luteolin 
amongst other potential active chemicals which may play a role in the beneficial activities of this 
plant (Van Wyk et al., 2000, Waithaka, 2004). Selected phytochemicals such as flavonoids may 
thus be appropriate markers to use to monitor quality aspects such as pharmaceutical quality and 
bioavailability of different A. afra plant preparations. Few studies have, however, addressed the 
ability of flavonoids to reach proposed in vivo sites of action. These limited number of studies 
conducted in humans and rats have indicated very poor and variable intestinal absorption of 
phenolic compounds (Walgren et al., 1998). In plants, flavonoids usually exist as glycosides and 
aglycones. The former is absorbed to a very limited extent (Scalbert and Williamson, 2000), are 
cleaved by gut bacteria (Day et al., 1999) and are usually hydrolysed (by intestinal enzymes 
and/or colonic micro flora) to the corresponding aglycone molecule (Manach et al., 2004; Pong 
et al., 2005) while the latter is absorbed freely across the intestinal mucosa by passive diffusion 
and conjugated in the mucosa and liver by phase II enzymes (Crespy et al, 1999). The 
mechanism by which flavonoids, whether as aglycone or glycosides are taken up into the cells of 
the gastrointestinal tract (GIT) has also not yet been fully resolved. Muganga found that the 
bioavailability of luteolin from aqueous extract of A. afra in the vervet monkey was significantly 
better than in its pure form (Muganga, 2004). It is thus speculated that either the plant extract 
might contain the luteolin in a better bioavailable glycoside form and/or might contain other 
compounds, which may beneficially influence the absorption characteristics of the flavonoid 
luteolin. Furthermore, an in vitro study should allow an insightful and more controlled approach 
to investigate the gastrointestinal permeability (i.e. absorption) of the flavonoid luteolin in the A. 
afra forms mentioned above before an in vivo study is conducted. 
Given the above arguments, the objectives of this study were to: (1) prepare the freeze dried 
aqueous extract (FDAE) and modified forms, viz. alginate-extract beads (alginate-FDAE) and 
polymethylmethacrylate coated alginate matrix beads (PMMA-alginate-FDAE) of the freeze 
dried aqueous extract of Artemisia afra, (2) determine and compare the pharmaceutical 
characteristics of the above mentioned preparations of A. Afra, (3) quantify and compare the total 
flavonoid and specifically luteolin levels of the different forms of A. afra,(4) evaluate and 
compare the release characteristics of FDAE of A. afra  from the alginate-FDAE and PMMA-
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alginate-FDAE beads in gastrointestinal fluids and (5) determine the intestinal permeability of 
luteolin in the A. afra plant forms. 
The literature reviewed in this study is covered in chapter 2; the plan of work in chapter 3; 
preparation and evaluation of different preparations of Artemisia afrain chapter 4; investigation 
of the in vitrobioavailability (permeability) of luteolin from modified A. afra forms in chapter 5 
and finally, the overall conclusion and recommendations are given in chapter 6. 
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Chapter 2 
Literature review 
 
2.1 Introduction 
In this chapter, an overview of Artemisia afra (A. afra) is given and this includes its botany, 
pharmacological effects, traditional uses and dosage form. In addition, this chapter also 
discusses: the shortcomings of the traditional preparation and methods of addressing them, the 
rationale for the preparation of modified forms of A. afra, an overview of flavonoids with focus 
on their chemistry and classification, and includes a brief description of the flavonoid luteolin 
with focus on its biological activities and pharmacokinetics as well as the rational for the use of 
the single pass intestinal perfusion (SPIP) method for investigation of the permeability of 
luteolin contained in the A. afra plant preparations. 
 
2.2 What is Artemisia afra? 
2.2.1 Vernacular names 
Artemisia afra is one of the oldest and best known traditional herbal medicines used in South 
Africa for the treatment of a variety of ailments (Watt and Breyer-Brandwijk, 1962, Van Wyk 
and Gerike, 2000). Locally, a variety of names relate to this plant such as “African wormwood” 
in English, “Umhlonyane” in Xhosa, “Mhlonyane” in Zulu, “Lanyana” in Sotho, “Lengana” in 
Tswana and “Wilde als” in Afrikaans (Burits et al., 2001, Watt and Breyer-Brandwijk, 1962). 
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2.2.2 Taxonomy and morphology (plant description) 
Artemisia afra belongs to the:      
Kingdom: Planta 
Family: Asteraceae 
Genus: Artemisia                                              
Species: A. afra  
Artemisia afra is a medium sized, erect growing multi-stemmed woody perennial shrub, which 
grows up to 2 m in height with a leafy, hairy-ridged stem (Van Wyk et al., 1997, Van der Walt, 
2004). Its soft leaves are finely-divided (like a fern), silver-grey due to the presence of fine hairs 
and grow up to 8 cm long and 4 cm wide (Figure 2.1). 
 
  
 
 
 
 
 
 
              Figure 2.1: Artemisia afra in its natural habitat at Montague gardens, South Africa. 
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2.2.3 Geographical distribution 
A. afra is a very common species and easily recognized medicinal plant in Southern Africa. In 
South Africa, it usually grows in rocky mountainous areas along forest margins and stream sides 
with its natural distribution extending from the Northern and Eastern Transvaal to the Western 
Cape. It is also wide spread in Kwazulu-Natal from the coast to the Drakensberg (Hilliard, 1977). 
Its geographical distribution in South Africa is shown in figure 2.2. 
 
 
Figure 2.2: Geographical distribution of A. afra in South Africa (Adapted from SATMERG Pharmacopoeia, 
Monographs Project, 1999). 
 
2.2.4 Uses and Pharmacological effects 
A. afra is exceptionally and widely used in many parts of the world either alone or in 
combination with other plants as herbal remedies for a variety of ailments ranging from 
relatively minute discomforts like simple headache to neurological disorders like epilepsy. In 
South Africa, its name “African wormwood” is derived from its ability to eradicate worms but it 
is also used in the treatment of numerous ailments including colds, coughs, heartburn, flatulence, 
bladder and kidney disorders, convulsions, diabetes, headache, inflammation, rheumatism and 
stomach disorders (Felhaber, 1997, Thring and Weitz, 2006). The infusions or decoctions are 
applied as a lotion to bathe haemorrhoids and for ear ache as well as for treatment of diabetes in the 
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Eastern Cape Province of South Africa (Erasto et al., 2005, Mahop and Mayet, 2007). In addition to 
these, it is also commonly used for the treatment of acute bronchitis, hay fever and, asthma as it 
is said to clear the respiratory and bronchial passages (Graven et al., 1990, Watt and Breyer-
Brandwijk, 1962, Hutchings et al., 1996b, Van Wyk and Wink, 2004).  
A. afra is known to have strong antihistaminic, narcotic and analgesic activities (Van Wyk et al., 
1997, Bruneton, 1995). Recent studies have demonstrated that steam distilled A. afra oil 
possesses antimicrobial properties (Graven et al., 1992). However, there is limited data on 
pharmacological investigations done on A. afra. 
 
2.2.5 Phytochemical constituents of Artemisia afra 
Artemisia afra contains many phenolic compounds which are dominated by flavonoids, a group 
of phytochemicals well known for their many biological activities (Harborne, 1973). However 
little is documented in the literature concerning the flavonoid constituents of A. afra. Although 
terpinoids, coumarins, acetylenes, scopoletin as well as triacontane and umbelliferone have been 
shown to be present in A. afra, their contribution to the biological activities of the plant is not yet 
known (Iwu, 1993, Van Wyk and Gerike, 2000). 
The flavonoids that have been isolated include luteolin, apigenin, quercetin, chrysosplenetin and 
a tetra-hydroxymethoxyflavone (Tang et al., 2000). Several studies done at the School of 
Pharmacy of the University of the Western Cape though unpublished, revealed the presence of 
the flavonoid luteolin, kaempferol, apigenin and quercetin leaf infusions and aqueous extracts of 
plant leaves (Waithaka, 2004, Komperlla, 2005, Mukinda, 2006) 
The essential oils of A. afra are known to contain mainly 1, 8-cineol, α-thujone, camphor, 
borneol, Artemisia ketone and sequiterpene -1-3 (Hutchings et al., 1996a{Hutchings, 1996 #319, 
Graven et al., 1990, Piprek et al., 1982). In addition, tannins, saponins, terpinoids, coumarins and 
acetylenes have been detected within the leaves of A. afra (SATMERG, 1999, Hutchings et al., 
1996a, Van Wyk et al., 1997). 
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2.2.6 Dosage form of Artemisia afra 
The usual dosage preparation of the plant is in the form of an infusion or decoction which 
involves the use of fresh leaves immersed in hot or boiling water and allowing it to seep to make 
a tea and as Wilde Als brandy, an alcoholic preparation. The leaf infusions are taken as teas or 
administered as enemas and the steam from the infusions arising from the Artemisia afra leaves 
is commonly inhaled for the treatment of headaches and colds (Hutchings et al., 1996). Enemas 
are made by suspending the ground A. afra plant in hot water or milk and the mixture used for 
constipation or intestinal worms in children. Decoctions are also taken as blood purifiers for 
acne, boils, measles and small pox (Bryant, 1996). The infusions or decoctions are made with 
variable quantities of fresh leaves and various forms of infusions are employed for treatment of 
diseases by different tribes (Roberts, 1990). However, despite the extensive traditional dosage 
forms (e.g. teas and enemas) and use of this plant, there is little or no data describing the 
effectiveness of these various dosage forms and the methods of use. 
 
2.2.7 Shortcomings of the traditional dosage form preparation 
The aforementioned traditional dosage forms of A. afra have several disadvantages arising from 
poor stability during storage and inconsistent directions for preparation and administration. 
Firstly, the use of wet leaves in the preparation of teas is inappropriate. This is because moisture 
present in the leaves may promote bacterial growth which may lead to deterioration of the 
product (McCutcheon, 2002). Secondly, directions for dosage preparations are often generally 
obscure for example; the use of inexact measures such as a quarter cup, a handful, tumblerful and 
calabashful in the directions to prepare and use the traditional dosage form makes the 
instructions vague and incorrect. This leads to lack of mass and content uniformity as it is 
difficult to accurately quantify a handful or measure a quarter cup consistently (Sofowora, 1982, 
Williamson et al., 1996). Thus, it may be anticipated that such variability in the preparation may 
lead to variations in dose each time a treatment is prepared thus altering the bioavailability and 
the pharmacokinetics of the active constituents. Thirdly, A. afra infusions or teas/decoctions are 
often smelly and awful tasting for oral use. Sweeteners e.g. honey and sugar is then added to 
these teas or infusions to make them more palatable and to improve patient acceptability. 
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However, these additives in turn act as good media for the growth of microorganisms like 
bacteria, mould and fungi (Burlage et al., 1963). Lastly, intake of tea decoctions can differ 
significantly depending on the method of preparation of the tea. The size of the leaves and the 
extraction surface seems to be important in relation to flavonoid content (Aherne and O'Brien, 
2002).   
In the traditional method of preparation, there is no mention of the expected degree of 
comminution of the A. afra leaves. Particle size largely explains the differences seen in flavonoid 
yield between tea prepared from tea bags and loose leaves. Tea produced from tea bags has 
higher flavonoid levels compared with tea prepared from loose tea leaves (Hertog et al., 1993). 
 
2.2.8 Lack of bioavailability data on the Artemisia afra plant 
There is no commercially available preparation of Artemisia afra that is registered with the 
Medicines Control Council of South Africa and there exists very limited data about their 
bioavailability and bioequivalence. Thus there is no pharmacokinetic basis for the recommended 
dosage regimens of the Artemisia afrapreparations due to the absence of pharmacokinetic data 
that usually results from bioavailability studies. Pharmacokinetics involves processes like 
absorption, distribution, metabolism and elimination and these processes have a crucial impact 
on the safety and efficacy of a medicine. The above mentioned pharmacokinetic processes are 
usually quantitatively described by means of various pharmacokinetic parameters such as 
volume of distribution, elimination or absorption half-lives or rate constants, and rates of 
excretion and metabolism. These parameters are obtained through pharmacokinetic studies and 
are important to support the labelling of drugs as well as for establishing dosage regimens 
(Shargel and Yu, 1999). For a new medicine, the pharmacokinetic parameters are usually 
determined in animal studies before the medicine is tested in humans (Spilker, 1991). This 
therefore implies that the proposed therapeutic effectiveness of A. afra is backed by very little or 
no evidence. The bioavailability and bioequivalence studies are usually conducted to 
quantitatively describe the absorption characteristics of a compound and to quantitatively 
compare the absorption of compounds respectively. The design of such studies is crucial to 
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obtain valid results. In this thesis, the focus is on investigating the permeability of luteolin in A. 
afra across the intestine as an indication of bioavailability. 
 
2.3 Need for modified forms of Artemisia afra plant 
As discussed in section 2.2.7 the traditional dosage form (i.e. tea, infusion, steam inhalation) of 
Artemisia afra has a number of disadvantages and are also not suitable for the evaluation of the 
herbal extract in clinical trials. Various studies conducted at the School of Pharmacy, University 
of the Western Cape,  have investigated the production of freeze dried aqueous extract of A. afra 
and its formulation into various dosage forms (e.g. tea bags, tablets and capsules) (Dube, 2006, 
Egieyeh, 2009). These attempts were aimed at achieving a consistent dosage form of A. afra with 
high quality that will be suitable for clinical trials. However, the major challenge encountered 
with these dosage forms thus far prepared was the hygroscopicity of the freeze dried aqueous 
extract (FDAE) of A. afra. The hygroscopic nature of the FDAE of A. afra and other herbal 
extracts has been a major challenge for many researchers and manufacturers in the herbal drug 
and nutraceutical industries. Attempts to formulate these herbal extracts into an acceptable 
standardised dosage form that can be used for clinical trials have been very daunting (Tong et al., 
2005). Hygroscopic and/or deliquescent substances, by definition, are prone to moisture sorption 
when exposed to environments with even moderate humidity. The sorption of moisture by drugs 
and herbals can create significant problems. Moisture can affect the physical, chemical and 
mechanical properties of a solid drug/herbal substance (Stubberud et al., 1996). There is 
therefore a general, and in the case of Artemisia afra, a specific need for a pharmaceutically 
acceptable non hygroscopic solid herbal formulation. In an attempt to achieve this, excipients 
were added to the prepared FDAE to further modify the form. The International Pharmaceutical 
Excipient Council (IPEC) defines an excipient as any substance other than the active drug that is 
included in the manufacturing process. Excipients are commonly used to improve the less than 
satisfactory characteristics e.g. pharmaceutical (i.e. excessive hygroscopicity) or 
pharmacokinetic (i.e. low bioavailability) of active ingredients. Excipients can also be used to 
prepare controlled or modified release preparations. These controlled preparations are usually 
multi-particle drug delivery systems suitable for achieving controlled or delayed release of oral 
formulations (Dey, 2008). Furthermore, they maintain adequate therapeutic plasma level of drug 
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avoiding peak-and-valley effect and thereby prolong the release of drug over extended period of 
time (Deasy and Dekker, 1984, Welling and Dobrinska, 1987). Tapas et al., used 
polymethylmethacrylate coated alginate matrix microcapsules to prepare a controlled release 
dosage form of diclofenac sodium which was found to have prolonged release in the intestine 
with improved absorption (Tapas et al., 2011).The release of drug from the matrix microcapsules 
was less than that from the non-matrix microcapsules. While the non-matrix microcapsule 
prepared released 100% drug in 12 h, the matrix microcapsules released only 76.06% drug in 12 
h. For this study, the freeze dried aqueous extract of A. afra was prepared and was further 
modified by adding alginate to the extract to prepare alginate-FDAE beads, and 
polymethylmethacrylate (PMMA) to prepare PMMA-alginate-FDAE beads. 
 
2.3.1 Freeze-dried aqueous extract 
Freeze drying the frozen aqueous extract allows water to be eliminated by sublimation. This 
operation allows drying to be conducted under moderate temperatures thus resulting in a high 
quality product. The freeze dried aqueous extract also has maximum antioxidant capacity since 
drying is done at moderate temperatures leading to reduced chemical degradation and less 
exposure to air during drying. 
As aqueous solutions, freeze drying will stabilize the extract in a solid powder form that can be 
repackaged, formed into tablets, encapsulated, or used for further processing. Freeze drying 
preserves the chemical integrity of the extract ensuring high potency and effectiveness.  In a 
stable, powder form, scientific studies on the extracts can be performed using known, repeatable 
quantities. Unfortunately, the solid particles formed from freeze drying of most aqueous extract of 
herbal medicines are hygroscopic. This leads to poor processing properties, poor stability of 
manufactured dosage forms and facilitation of microbial contamination (Schiller, 2002), thus the 
modification into less hygroscopic forms by incorporating excipients such as alginate, dextran 
and polymethylmethacrylate. 
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2.3.2 Alginates 
Alginate is a natural biopolymer composed of randomly distributed units of two sugars which are 
urinates, 1, 4-linked β-D-mannuronic and α-L-guluronic acid residues (George and Abraham, 
2006). Alginate, a hydrogel, is used as an excipient for the formulation of beads because of its 
ability to absorb 200-300 times its own weight of water (Rowe et al., 2009). Biopolymers like 
alginate have been shown to improve the gastrointestinal uptake of poorly absorbable drugs like 
insulin by entrapment of the protein to provide degradative protection in the gastrointestinal tract 
and facilitate transport into the systemic circulation (Sarmento et al., 2007). In addition, the 
encapsulation process using alginate hydrogels in the formation of the calcium alginate beads is 
done under extremely mild conditions and uses non-toxic reactants (Song et al., 2012). Alginate 
was chosen because as part of controlled release technology, it has advantages such as lower 
consumption of the active agent, reduced frequency of administration, and minimized side 
effects of drugs. Calcium alginate beads formed are spherical and are expected to improve the 
flowability of the freeze dried aqueous extract of Artemisia afra. Figure 2.3 shows the structures 
of mannuronic and guluronic acid residues and the linkage between these residues in alginate in 
the presence of calcium ions. 
 
 
 
Figure 2.3: Chemical structure of alginate and its schematic gelation mechanism in the presence of calcium 
ions. Shown is a polymer chain of 2 guluronic acid (G) monomers and 2 mannuronic acid (M) 
monomers, with (1–4) linkages (George and Abraham, 2006). 
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2.3.3 Polymethylmethacrylate 
Polymethylmethacrylate can be used as a coating polymer to produce a multiunit controlled 
release dosage form, which maintains adequate therapeutic plasma level of drug and prolongs the 
release of drug over extended period of time (Tapas et al., 2011). One of the objectives of this 
study was to develop PMMA coated alginate matrix microcapsules by W1/O/W2 emulsion 
solvent method and to compare its release profile with the other preparations mentioned above. 
Figure 2.4 shows the chemical structure of polymethylmethacrylate. 
                        
                               Figure 2.4: Chemical structure of Poly (methyl methacrylate). 
 
2.4 Use of single pass intestinal permeability (SPIP) method to investigate 
 permeability and absorption of modified forms of Artemisia afra 
Despite tremendous innovations in drug delivery methods in recent decades, the oral route of 
drug administration still remains the most preferred route for most drug entities. The oral route of 
administration of drugs is preferred by virtue of the fact that it is convenient, inexpensive and 
offers high patient compliance as compared to alternate routes (Balimane et al., 2000). However, 
compounds intended for oral administration must have adequate aqueous solubility and intestinal 
permeability in order to achieve therapeutic concentrations. Poor permeability and/or absorption 
makes a molecule unsuitable for further development, and there has been great interest recently 
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in finding ways to avoid the situation of having a potent, yet impermeable molecule. Thus, 
prediction of drug absorption and permeability is therefore very important for the design of an 
oral preparation. For several decades, human in vivo studies using earlier intestinal techniques 
have been applied to investigate absorption, permeability and gastric emptying. Although human 
in vivo studies will be the most desirable, they are difficult, expensive and time consuming to 
conduct. As a result, a number of in vitro and in situ experimental methods have so far been 
utilised to estimate gastrointestinal absorption of drugs and the mechanism of absorption.  
Animal tissue-based methods like the everted gut technique, isolated membrane vesicles and the 
in vitro transport across intestinal segment (side-by-side Ussing chamber) have been extensively 
used to explore the mechanism of absorption of nutrients from the intestine (Wilson and 
Wiseman, 1954, Ussing and Zerahn, 1951). Animal intestinal tissues are made up of essentially 
the same kind of endothelial cells as human tissue and have thus been extensively used because it 
is extremely difficult to obtain viable human tissues for permeability studies on a regular basis. 
However, the viability of the excised tissues is difficult to maintain since the tissues are devoid 
of direct blood and nerve supply and need constant oxygenation. Other disadvantages of these 
methods include rapid loss of viability of the tissues during the experiment and changes in 
morphology and functionality of transporter proteins during the process of surgery and mounting 
of tissues. Cell-based methods like caco-2 cells and TC-7 clone have been the most extensively 
characterized and useful cell model in the field of drug permeability and absorption (Artursson et 
al., 1994, Rubas et al., 1996). The predictability and utility of this model to rank order a large 
number of compounds in terms of absorption potential have been demonstrated many times by 
many investigators (Artursson and Karlsson, 1991, Chong et al., 1997). However, this method 
has a shortcoming in that it is very difficult to compare the absolute permeability coefficient 
value of individual compounds, particularly with compounds that primarily permeate via the 
paracellular route. Among these methods, the in situ method, single-pass intestinal perfusion 
(SPIP) approach is one of the most widely used classic technique employed in the study of 
intestinal absorption compounds, which provides experimental conditions closer to what is faced 
after oral administration (Crouthamel and Sarapu, 1983, Sutton et al., 2001). The biggest 
advantage of this technique is the presence of an intact blood and nerve supply. In addition, the 
technique has lower sensitivity to pH variations because of a preserved microclimate above 
epithelial cells (Hogerle and Winne, 1983). The technique also provides the unique advantages 
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of experimental control (compound concentration and intestinal perfusion rate) and the ability to 
study regional differences; and factors that may influence the intestinal absorption of the 
compound. 
In situ perfusion of intestinal segments of rodents (rats or rabbits) is frequently used to study the 
permeability and absorption kinetics of drugs and it involves perfusion of drug solution prepared 
in physiological buffer through isolated cannulated intestinal segments. Permeability is assessed 
based on the disappearance of drug (difference between inlet and outlet concentrations) from 
intestinal lumen. Since water absorption and secretion during the perfusion may cause errors in 
the calculated net effective permeability values (Peff), a non-absorbable marker is required to 
correct water reflux (Sutton et al., 2001). For this reason, phenol red is co-perfused with drug 
compounds.Phenol red was first introduced as a non-absorbable marker by Gorham in 1923 
(Gorham, 1923). 
Previous studies have shown that the extent of absorption in humans can be predicted using the 
single pass intestinal perfusion in rat (Salphati et al., 2001). However, the single pass intestinal 
perfusion method is limited in that the method relies on the disappearance of compound from the 
luminal side as an indication for absorption. Moreover the rate of absorption of drug into the 
systemic circulation is not always represented by the rate of decrease of concentration in the 
perfusate. Uhing and Kimura also demonstrated that the surgical manipulation of the intestine 
combined with anaesthesia caused a significant change in the blood flow to the intestine and had 
a remarkable effect on absorption rate (Uhing and Kimura, 1995). In this study, the single pass 
intestinal perfusion was employed to investigate the permeability and absorption of flavonoids 
from the different modified preparations of Artemisia afra. The limitations mentioned above 
affected this study in that the concentration of luteolin indicated by the effluent perfusate 
samples was not an exact representative of the concentration of luteolin absorbed into the 
systemic circulation. In addition the incisions made on the intestine were seen to reduce the 
blood flow to the intestine thus affecting the concentration of luteolin absorbed into systemic 
circulation. 
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2.4.1 Criteria for selection of animal model for permeability study 
Interspecies differences in gastrointestinal (GI) transit time, size and shape of intestinal villi, 
gastric pH, lymphatic uptake and drug metabolism occurring in the gut are among the 
physiological variables that can contribute to differences in absorption (Rogge and Taft, 2005) 
and consequently, in the bioavailability of a drug material. Much of the interspecies’ diversity in 
GI anatomy and function reflects differences in primary sources of dietary constituents (Rogge 
and Taft, 2005). In light of these interrelationships, the basis for selection of an animal model for 
bioavailability studies should be on the closeness of evolutionary and dietary similarities to man. 
 
2.5 Flavonoids 
Flavonoids are a class of polyphenolic compounds that occur naturally in the plant kingdom. 
They occur ubiquitously in virtually all plant parts including the leaves, roots, wood, bark, 
pollen, flowers, berries and seeds (Markham, 1982). They are common dietary components of 
vegetables, fruits, wine and tea. They are the pigments responsible for the various colours 
observed in flowers and are also required for the normal growth, development and defence 
mechanisms in plants (Di Carlo et al., 1999, Harborne and Williams, 2000). 
 
2.5.1 Chemistry and classification 
Flavonoids are a group of low-molecular weight phenolic substances formed from the 
combination of derivatives synthesized from phenylalanine and acetic acid. All flavonoids have a 
common biosynthesis origin namely, a chalcone resulting in condensation of a “triacetate’’ with 
cinnamic acid, and cyclization forming the central pyran ring (Bruneton, 1999). The structure of 
flavonoids is based on the flavonoid nucleus (Figure 2.5), which consists of 3 phenolic rings 
referred to as A, B, and C rings (Kuhnau, 1976).  
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                                          Figure 2.5: General structural formula of flavonoids. 
 
The flavonoids are divided into various classes according to the position of multiple 
combinations of hydroxyl groups, sugars, oxygen, and methyl groups attached to the basic 
structure. Variations in the heterocyclic ring C give rise to flavonols, flavones, catechins, 
flavanones, anthocyadins and isoflavonoids (Figure 2.6) (Di Carlo et al., 1999, Markham, 1982). 
In addition, the basic structure of flavonoids allows a multitude of substitution patterns in the 
benzene ring A and B within each class of flavonoids: phenolic hydroxyls, O-sugars, methoxy 
groups, sulphates and glucuronides. Flavonoid per se are compounds in which the benzenoid 
substitution is at the 2-position while compounds with substitution at 3-position are termed 
isoflavonoids. Flavonoids may also be aglycones (i.e. consisting of benzene ring condensed with 
a six-member ring, which possesses a phenyl ring at the 2 position), glycosides (that carry one or 
more sugar residues on the ring) or methylated derivatives.  
Flavonoids containing a pyran ring i.e. a hydroxyl group in position C3 of the C ring are 
classified as 3-hydroxyflavonoids (i.e. the flavonols, anthocyanidins and catechins) and those 
lacking a hydroxyl group in position C3 as 3-desoxyflavonoids i.e. the flavanones (e.g. 
hesperetin, naringenin) and flavones (e.g. luteolin, apigenin) (Markham, 1982, Heim et al., 
2002). In this study, luteolin is the main flavonoid of interest and is further discussed below. 
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                                   Figure 2.6: Structures of the main classes of flavonoids. 
 
 
2.5.2 Metabolism and bioavailability of flavonoids 
The metabolism and bioavailability of flavonoids is likely to be of crucial importance to their 
ability to help protect human health against disease (Setchell et al., 2002). Deglycosylation of 
flavonoid glycosides has been proposed as the first stage of metabolism. Day et al. used human 
small intestine and liver cell-free extracts to see whether there is glucosidase activity toward 
flavonoid glycosides. Some but not all flavonoid glycosides were hydrolysed by the small 
intestine and liver extracts (Day et al., 1998). After absorption, flavonoids are bound to albumin 
and transported to the liver via the portal vein (Manach et al., 1996). The liver seems to be the 
chief organ involved in flavonoid metabolism; nevertheless, it must be noted that other tissues, 
especially intestinal mucosa or kidneys must not be ruled out (Hackett, 1986). The liver also 
synthesizes conjugated derivatives, by coupling with a sulphate or a glucoronic acid molecule.  
The conjugated flavonoid derivatives are excreted in urine and in bile, the major route depending 
on the species. When excreted in bile, they are poured into the duodenum and metabolized by 
bacteria in the large intestine, which results in the production of fragmentation products and/or 
the hydrolysis of glucorono- or sulpho-conjugated and the release of flavonoid metabolites. 
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These may be reabsorbed and undergo an enterohepatic cycling, thus non negligible 
concentrations of flavonoid metabolites may be present in the blood plasma. 
Flavonoid metabolism in humans has been reported to also depend on the participation of 
intestinal microflora (Kuhnau, 1976, Bokkenheuser et al., 1987, Griffiths, 1982). Flavonoids that 
are not absorbed in the small intestine can be metabolized by colonic microflora into aglycones 
and phenolic acids. These in turn may be absorbed from the colon (Manach et al., 1998, Hollman 
et al., 1995, Macdonald et al., 1983). Flavonoid metabolism produces a series of phenolic 
compounds that have been identified as aromatic acids. They form by detachment of the A ring 
from the residual flavonoid molecule and the opening of the heterocyclic C ring. 
 
2.6 Luteolin 
Luteolin is a yellow microcrystalline substance which is an active compound in Reseda luteola 
L. (Hoppe, 1975) found by Chevreul in 1833. In 1896, Pekin confirmed the presence of luteolin 
in weld. Paris later isolated, characterized and identified luteolin glycoside in 1955 (Cristea et al., 
2003). It is sparingly soluble in water, but soluble in alkali. 
Luteolin is one of the most common flavonoids present in edible plants and in plants used in 
traditional medicine to treat a wide variety of ailments. It is most often found in leaves, barks, 
clover blossom, rag weed and pollen.  
Luteolin is present as an aglycone (molecule without any sugars bound to it) in some plants such 
as perilla seeds and as glycosides (molecule with one or several sugars bound to it) in celery, 
green pepper, perilla leave, chamomile tea, etc. (Shimoi et al., 1998, Shimoi et al., 2001). Most 
glycosides of luteolin are O-glycosides, i.e., the sugar moieties are bound to the aglycone 
through one or more four free hydroxyl (OH) groups (Figure 2.7). These glycosides usually have 
sugar moieties at position 5, 7, 3’ and 4’, as luteolin is 5, 7, 3’, 4’- tetrahydroxyflavone (Lopez-
Lazaro, 2009).  
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                                         Figure 2.7: The structure of Luteolin and Luteolin-7-0-glucoside. 
 
2.6.1 Biological activities of luteolin 
Luteolin may be a valuable available emerging pharmacological agent due to its many beneficial 
properties. It has been reported that luteolin has anti-inflammatory and antispasmodic activity 
(Hoffmann, 1995), antioxidant activity (Areias et al., 2001), anti-allergic and, anti-cancer 
activities and immune-modulatory properties to suppress hyperactive immune systems (Shimoi 
et al., 1998). Due to its anti-allergic, anti-inflammatory and smooth muscle relaxing properties, 
luteolin has potential in the prevention and treatment of many respiratory disorders including 
asthmatic conditions and chronic bronchitis (Wang, 2000). Luteolin has been demonstrated to be 
an emerging anti-cancer agent that completely inhibits the catalytic activity of eukaryotic DNA 
topoisomerase I. (Chowdhury et al., 2002, Galvez et al., 2003). Luteolin is an important dietary 
cancer preventive agent (Cai et al., 1997, Elangovan et al., 1994, Ubeda et al., 1995) and shows 
strong antiproliferative activity against different human cancer cell lines (Ramanathan et al., 
1993, Fotsis et al., 1997). Luteolin is also known to be an effective smooth muscle relaxant and 
protects the heart lipids against doxorubicin-induced lipid peroxidation (Sanchez de Rojas et al., 
1996, Sadzuka et al., 1997). Luteolin also aids in prevention of the neovascular disease of the eye 
by inhibiting corneal angiogenesis in vivo (Joussen et al., 2000). 
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Based on this profile of action, luteolin, thus, appears to be one of the potential pharmacological 
constituents that could contribute to the medicinal values of many plants. However, very limited 
information is available on the absorption and bioavailability of luteolin in human or in 
experimental models.  
 
2.6.2 Absorption and metabolism of luteolin 
Very few studies have been done demonstrating the ability of flavonoids to reach proposed sites 
of action in vivo.  The limited number of studies in rats and humans has indicated very poor and 
variable intestinal absorption of phenolic compounds (Walgren et al., 1998). It is generally 
assumed that flavonoids are absorbed as their aglycones after hydrolysis of the glycosides along 
the digestive tract (Walle, 2004). However controversies exist concerning which form of 
flavonoid is actually absorbed i.e. glycoside, aglycone or both forms. Glycosides are absorbed to 
a very limited extent (Scalbert and Williamson, 2000) are cleaved by gut bacteria (Day et al., 
2000) and are usually hydrolysed (by intestinal enzymes and/or colonic micro flora) to the 
corresponding aglycone molecule (Manach et al., 2004, Pong  et al., 2005). Aglycones on the 
other hand are absorbed freely across the intestinal mucosa by passive diffusion and conjugated 
in the mucosa and liver by phase II enzymes (Crespy et al., 1999). Kuhnau, 1976, reported that 
flavonoids present in foods cannot be absorbed from the intestine because they are bound to 
sugars as glycosides and further explained that only free flavonoids without a sugar molecule 
(aglycones) are considered to be able to pass through the gut wall (Kuhnau, 1976). In contrast, 
Hollman and his team (1999) suggest that for quercetin glycosides, the absorption of the intact 
glycosides is much better than the pure aglycones (Hollman and Katan, 1999). In addition, the 
mechanism through which flavonoids are absorbed in the GIT whether as aglycones or 
glycosides has not yet been fully resolved. It is however generally assumed that the aglycones of 
the flavonoids are absorbed mainly by passive diffusion (Pong  et al., 2005). 
The metabolism of flavonoids after absorption may have a considerable effect on their biological 
properties (Nielsen et al., 1997, Erlund et al., 2002) and bioavailability. The liver seems to be the 
chief organ involved in flavonoid metabolism (Hackett, 1986). Other important sites of flavonoid 
metabolism include the gastrointestinal lumen, cells of the intestinal wall (Erlund et al., 2002). 
Day et al., showed that the enzymes lactase–phloridzin hydrolase and ß-glycosidase were able to 
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cleave flavonoid glycosides in the small intestine although it wasn’t yet well characterized (Day 
et al., 1998, Day et al., 2000).  There is also evidence suggesting that flavonoids can be 
metabolized prior and during absorption and be subject to first-pass metabolism (Scalbert and 
Williamson, 2000, Shimoi et al., 1998, Erlund et al., 2002).  
Spencer et al., investigated the absorption of luteolin aglycone and luteolin 7-O-ß-glucoside 
through the perfusion of the jejunum and ileum in an isolated rat intestine model. They found at 
least six different glucoronides in the plasma after treatment with ß-glucoronides (Spencer et al., 
1999). The results suggested that luteolin was mono-glucoronidated at different sites and could 
also possibly be di- or tri- glucoronidated. Shimoi et al investigated the absorption of luteolin 
and luteolin 7-0-ß-glucoside in rats by High-Performance Liquid Chromatography (HPLC) using 
rat everted small intestine. The absorption analysis demonstrated that luteolin was converted to 
glucoronides during passing via the intestinal mucosa and that luteolin 7-0-ß-glucoside was 
absorbed after hydrolysis to luteolin. They confirmed that free luteolin, its conjugates and 
methylated conjugates were present in rat plasma after its oral administration in pure form and 
that some luteolin could possibly escape the intestinal conjugation and the hepatic 
sulfation/methylation (Shimoi et al., 1998). 
Very few studies have however been done on the pharmacokinetics of luteolin contained in plant 
materials. Wittemer et al., investigated the bioavailability of luteolin glycosides contained in 
Artichoke leaf extracts in humans. It was found that no free luteolin or luteolin-7-O-glucoside 
was present in plasma or urine (Wittemer et al., 2005). Muganga found that the bioavailability of 
luteolin from aqueous extract of Artemisia afra in the vervet monkey was significantly better 
than in its pure form (aglycone) (Muganga, 2004). Thus there is a need to know in which of the 
modified forms luteolin will be better absorbed from the plant. 
 
2.6.3 Analytical methods suitable for luteolin analysis in plants and use in bioavailability 
studies 
Several methods are used to separate, identify and quantitate flavonoids in plant material. 
Several steps are involved in these methods which include separation, purification and 
identification of the different constituents that may be present in the plants. For both quantitative 
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and qualitative analysis, a very important step is proper preparation of the sample, which differs 
depending on: 
1) The physical state of the sample (fluid or solid). 
2) The concentration of the compound in the sample (flavonoids in biological samples are 
usually at a fairly low level, so it may be necessary to enrich the sample by extraction). 
3) The type of matrix containing flavonoids (particular components of a matrix may 
interfere with the analyte, making the analysis difficult). 
4) The chemical nature of the analysed compound. Flavonoids in physiological human 
materials and in plant samples are most frequently in the form of conjugates: in food 
samples, they mainly occur as glycosides, whereas in the material isolated from animals 
and humans, the most forms are glucoronic or sulfonic derivatives. 
Many solvents can be used to extract the flavonoids found in plants, depending on the form of 
the flavonoid (aglycone or glycoside). To extract flavonoids in aglycone form, non-polar 
solvents such as ether, hexane and chloroform are usually used (Markham, 1982). Glycosides or 
flavonoids possessing a number of un-substituted hydroxyl groups are polar and generally 
soluble in solvents such as ethanol, methanol, dimethyl sulfoxide and water. 
Several chemical tests and calorimetric methods can be used to identify individual flavonoids or 
flavonoid classes. One of such methods is thin layer chromatography (TLC) which is a very 
useful and frequently applied technique (Markham, 1982). However, most flavonoids are not 
visible on TLC plates and are therefore viewed under ultraviolet light at wavelengths 254 and 
366 nm after the spots have been exposed to ammonia vapours. The TLC technique has a very 
low sensitivity and a low limit of detection of 5-10 µg flavonoid on the plate (Wagner et al., 
1984). Therefore, high performance liquid chromatography (HPLC) which is a sensitive and 
rapid technique is increasingly utilised for the separation, identification and quantification of 
flavonoids in plant extracts (Springfield et al., 2005). Indeed, HPLC and mass spectrometry are 
modern techniques used for identification and quantitative analysis of flavonoids (Harborne and 
Williams, 2000) and several studies have indicated the successful use of HPLC for the 
 
 
 
 
25 
 
identification and quantification of flavonoids (Cristea et al., 2003, Wittemer and Veit, 2003, 
Valentao et al., 1999). 
Reversed-phase HPLC (RP-HPLC) combined with different detectors is also a commonly used 
analytical method for separation of flavonoids (Escarpa and Gonzalez, 1998, Brolis et al., 1998). 
RP-HPLC is also being used because flavonoids are usually very soluble in polar solvents. 
Several steps are involved in the analyses of flavonoids. The first step is the acid hydrolysis of 
the aqueous plant material followed by organic phase extraction to separate the free aglycones 
from the other flavonoids and the use of HPLC to isolate individual compounds (Tura and 
Robards, 2002). In developing the HPLC assay for analyses, selection of suitable solvents, 
columns and wavelengths of maximum absorption are taken into consideration. In HPLC assays, 
various proportions of solvents such as water-methanol, water-methanol-acetic acid or formic 
acid and water-acetonitrile have been reported for the elution of flavonoids such as luteolin and 
hesperetin (Markham, 1982). The most popular HPLC stationary phase used both generally and 
specifically for analyses of phenolics is octadecylsilane (ODS, C18, RP-18) (Majors, 2001). The 
final step in the analysis of flavonoids is the measurement of the detector response, development 
of the calibration curve and validation of the assay. Suitable HPLC assays can thus be developed 
and used to quantify flavonoids such as luteolin in plant material and can also be used to 
compare and investigate the bioavailability (cell membrane permeability) of luteolin from 
different preparations of the A. afra plant extract (i.e. FDAE vsalginate-FDAE vs PMMA- 
alginate-FDAE). 
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Chapter 3 
Plan of work 
 
3.1 Introduction 
This chapter outlines the specific objectives, hypotheses set, and the study approach used for the 
investigation of the in vitro bioavailability (i.e. gastrointestinal permeability) of luteolin from 
modified forms of A. afra. 
 
3.2 Study objectives 
The specific objectives of this study were: 
1. To prepare the freeze dried aqueous extract (FDAE) and  its modified forms, alginate – 
extract beads (alginate-FDAE) and polymethylmethacrylate coated alginate matrix beads 
of herbal extract (PMMA-alginate-FDAE) of the freeze-dried aqueous extract of A. afra, 
2. To determine and compare the pharmaceutical characteristics of the above mentioned 
preparations of A. afra, 
3. To quantify and compare the total flavonoid (and specifically luteolin levels) of the 
different forms of A. afra, 
4. To evaluate and compare the release characteristics of FDAE of Artemisia afra  from the 
alginate-FDAE and PMMA-alginate-FDAE beads in simulated gastric fluid (SGF) and 
simulated intestinal fluid (SIF) and, 
5. To determine the intestinal permeability of luteolin contained in the selected in selected 
modified A. afra extractpreparations. 
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3.3 Hypotheses of the study 
The following hypotheses were postulated; 
1) Hypothesis 1: making the alginate beads and the polymethylmethacrylate coated alginate 
matrix beads of the FDAE of A. afra makes the FDAE less hygroscopic with a lower 
moisture content i.e. 
      HFDAE> Halginate-FDAE > HPMMA-alginate-FDAE 
and 
      MCFDAE> MCalginate-FDAE > MCPMMA-alginate-FDAE 
 
Where H = hygroscopicity and MC = moisture content 
 
2) Hypothesis 2: the rate of release of luteolin from A. afra FDAE into gastrointestinal 
fluids is faster than the release from the alginate-FDAE and PMMA-alginate-FDAE 
beads and the rate of release of luteolin from A. afra alginate-FDAE faster than that from 
A. afra polymethylmethacrylate coated alginate matrix beads i.e.  
 
      RRFDAE> RRalginate-FDAE > RRPMMA-alginate-FDAE 
 
Where RR = rate of release 
 
3) Hypothesis 3: the effective gastrointestinal permeability (Peff) of luteolin in the alginate-
FDAE and PMMA-alginate-FDAE beads of A. afra FDAE is equal to that in FDAE i.e. 
     Peff
lut
FDAE   =   Peff
lut
modified extract 
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3.4 Study Approach 
To realize the above objectives, the following were done. Firstly the modified preparations of 
Artemisia afra were prepared and pharmaceutically characterised. Next, an HPLC assay for 
luteolin in plant samples was developed and the level of luteolin determined in the different 
preparations of Artemisia afra. Finally, this assay was used to determine the in vitro 
bioavailability i.e. gastrointestinal permeability, of luteolin in the A. afra forms using the in-situ 
perfused rat intestine model. 
 
3.4.1 Rationale for the modified preparations of A. afra freeze dried aqueous extract 
In traditional practise, A. afra is mainly used as an infusion or decoction of the loose leaves in 
hot water and these forms have a number of disadvantages as highlighted in chapter 2. Past 
researchers investigated the formulation of freeze driedaqueous extract of A. afra into a dosage 
form in an attempt to produce a more uniform dosage form. However, the major challenge 
encountered in this dosage form was the problem of hygroscopicity. Thus in this study, the 
FDAE was modified by the incorporation of excipients in an attempt to counter hygroscopicity 
(e.g. use of alginate) and alleviate issues of sub-optimal bioavailability of plant actives (e.g. 
polymethylmethacrylate). 
Alginate, a hydrogel, was used as an excipient in the formation of the beads because of its ability 
to absorb 200-300 times its own weight of water (Rowe, 2009). In addition, the beads are 
formedunder extremely mild environment from sodium alginate by ionic gelation, a process 
which takes advantage of the ability of sodium alginates to form solid gels by reaction with 
divalent cations such as Ca
2+
 (George and Abraham, 2006). The calcium alginate is expected to 
provide a barrier to diffusion of moisture into the herbal extract thus reduce the hygroscopicity of 
freeze dried aqueous extract of Artemisia afra. Polymethylmethacrylate was used as a coating 
polymer to reduce hygroscopicity andproduce a multiunit controlled release, which maintains 
adequate therapeutic plasma level of drug and prolongs the release of drug over extended period 
of time. PMMA-alginate-FDAE and alginate-FDAE beads are spherical and are expected to 
improve the flowability of the freeze dried aqueous extract of Artemisia afra. 
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3.4.2 Rationale for the selection of the characteristics to evaluate the forms of A. afra
 prepared 
To establish the pharmaceutical quality of these A. afra plant preparations certain organoleptic 
and pharmaceutical characteristics were chosen to be determined and compared viz, colour, taste, 
odour, texture, particle size, particle shape, moisture content (hygroscopicity), aqueous 
solubility, entrapment efficiency of FDAE in modified forms and total flavonoid content of A. 
afra forms. These parameters affect the physico-chemical properties, bulk properties, product 
performance, processability, stability, bioavailability, appearance of end product and play a great 
role in producing homogeneity of dosage forms, thus their evaluation is of paramount 
importance.Organoleptic properties were determined using natural senses while the 
pharmaceutical properties were determined using pharmacopoeial methods and those standard 
methods adapted from other workers. 
 
3.4.3   Rationale for the focus on luteolin 
Flavonoids form one of the major constituents of medicinal plants. In recent years, flavonoids 
have attracted increasing attention due to their various beneficial pharmacological effects. 
Luteolin was selected for this investigation firstly because it has been found as a major flavonoid 
constituent in the crude extracts of A. afra (Waithaka, 2004). Secondly, luteolin has been shown 
to have in vitro pharmacological activities as mentioned in the previous chapter that can be 
associated with the uses and in vivo effects of A. afra and therefore should be a reliable 
pharmacological marker agent whose pharmacokinetic characteristics will have a major impact 
on the therapeutic effect of this plant. In addition, flavonoid levels in the aqueous extracts of the 
plant could be easily quantified by HPLC assay because it is a sensitive, economic and rapid 
technique. Lastly, luteolin is found in A. afra in both aglycone and glycoside forms and would 
thus be an ideal marker compound to establish the effect the different preparations may have on 
the absorption and permeability of these different flavonoid forms. 
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3.4.4 Rationale for the use of single-pass intestinal perfusionmodel  
The in situ method, single-pass intestinal perfusion (SPIP) approach provides experimental 
conditions closer to what is faced after oral administration (Crouthamel and Sarapu, 1983, Sutton 
et al., 2001). The biggest advantage of this technique is the presence of an intact blood and nerve 
supply. In addition, the technique has lower sensitivity to pH variations because of a preserved 
microclimate above epithelial cells (Hogerle and Winne, 1983).On the other hand, the rat 
perfusion model was considered suitable for this study because,  
1. Laboratory rats have been shown to be similar to humans in many of their biochemical 
responses to drugs, including the absorption, distribution, metabolism and excretion of 
drugs. Thus, human biological, behavioural and many other characteristics can be 
replicated in rats. Moreover, if interpreted with due care, the extrapolation of the 
biological results obtained with these animals to humans may be considered valid.  
2. These experimental animal species are small, easily maintained and can, with practice, be 
easily handled in addition to the fact that they can be housed in large numbers in a 
relatively small area.  
3. Rats are relatively inexpensive and can be bought in large quantities from commercial 
producers that breed rodents specifically for research. The rodents are also generally mild 
tempered and docile, making them easy to handle although some types of rats can be 
more difficult to restrain than others. 
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Chapter 4 
Preparation and evaluation of different preparations of Artemisia 
afra 
 
4.1 Introduction 
In this chapter, the equipment, materials and methods used for the preparation of the freeze dried 
aqueous extract (FDAE) of A. afra and the modified forms of the FDAE of A. afra i.e. the 
alginate-FDAE beads and the PMMA-alginate-FDAE beads, are discussed. The organoleptic and 
pharmaceutical properties of A. afra preparations are also presented. The development and 
validation of the HPLC assay used for quantitation of luteolin in A. afra preparations is also 
described in detail. Finally, the results obtained are presented and discussed. 
 
4.2 Equipment, Chemicals and materials 
4.2.1 Equipment 
Analytical  balance (Mettler®, model PE 6000), a scientific balance (Ohaus®, model GA 110), a 
freeze- dryer (Virtis ®, Freeze mobile model 125L), -85°C freezer (Lozone CFC Freezer, Model 
U855360, New Brunswick Scientific, USA), a water bath (Labcon®, model CDH 110 
Maraisburg, SA), filtration system (SUPELCO) connected to vacuum pump (Medi-Pump Model 
1132-2, Thomas Industries, Inc., USA), filter paper (Whatman No. 41 & Whatman No.1, 
Whatman, England), oven (Model Memmet 854 Schwabach, West Germany), a centrifuge 
(Multex MSE®, England), desiccators, a microplate reader (VERSAmax, Molecular Device, USA), 
a vortex mixer (Vortex-2, G-560E, Scientific Industries, Inc. Bohemia, N.Y. 11716 USA), test 
sieve shaker (Endecott sieve shaker, E.F.L. 1MK11, Endecotts (test sieve) LTD, London, 
England), a pH meter (Basic 20 Crison Instruments, S.A, Italy), micropipettes, an HPLC system 
(Agilent model 1200, Chemetrics) consisting of an auto sampler and a diode array detector, all 
used with a C18 reverse phase column (Phenomenex,USA) having 4µm particle size and a 
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column length of 250 x 4.60 mm, HPLC filter unit (Millipore Cameo 25 AS, DDA 02025So MSI: 
Micro separation Inc., USA). 
 
4.2.2 Chemicals 
Acetonitrile and methanol, were purchased from Burdick & Jackson (USA), ethanol and 
aluminium chloride from Merck (Darmstadt, Germany), formic acid and sodium acetate from 
BDH Chemicals Ltd (England), hydrochloric acid from Kimix (USA), monobasic potassium 
phosphate, distilled water (prepared with Millipore filtration system) and ethyl acetate  from 
Saarchem, (South Africa), calcium chloride  from EMD Biosciences (Germany), sodium 
hydroxide and sodium alginate from Sigma Aldrich (Germany), polymethylmethacrylate, 
calcium chloride, dichloromethane, Tween 80, Span 80, luteolin, morin, pepsin and pancreatin 
were purchased from Sigma Aldrich (Germany).  All other materials and reagents were either of 
analytical grade or of the highest purity and used as received. 
 
4.2.3 Materials 
Dried A. afra leaves were purchased from local industrial herbal supplier Grassroot Group (Pty) 
Limited (Groenvlei farm, South Africa), placed in plastic bags and stored in a cool place at room 
temperature away from sunlight until use. 
 
4.3 Methods 
4.3.1 Preparation of the freeze-dried aqueous extract 
The study plant material was extracted in a way that closely mimicked the method traditional 
herbal practitioners have, as described in the literature, used over generations, to extract their 
plant medicines. Usually, a quarter cup quantity of A. afra leaves and a cup of boiling water is 
allowed to stand and steep for 10 minutes (Roberts, 1990). However, in this study, the dried 
leaves were suspended in distilled water (100 g of dried leaves in 3.5 L of distilled water) and the 
mixture boiled for 30 minutes.  Three batches were prepared. After boiling, the decoction 
obtained was left to cool before it was filtered using Whatman no. 1 filter paper and the filtrate 
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transferred to a round bottom flask and frozen at -85 °C in a freezer. The frozen extract was then 
dried under vacuum over 3 days using the Virtis™ mobile freeze-dryer. The resultant extract 
powders from the different batches were then combined into a single final homogenous batch 
and weighed to determine the percentage yield. Finally, the FDAE powder was placed in 
stoppered amber glass bottles and stored at room temperature in desiccators until used. 
 
4.3.2 Preparation of alginate beads (alginate-FDAE) of aqueous extract of Artemisia afra 
The stock solution was prepared by dispersing 2 g of FDAE into appropriate volumes of sodium 
alginate solution (4% w/w). The calcium-alginate beads were prepared by drop wise addition of 
10 ml of the stock solution into 20 ml of CaCl2 solution (5% w/w) through a stainless steel 
needle with a diameter of 0.7 mm (Song et al., 2012). In this process, the distance between the 
edge of the needle and the surface of the CaCl2 solution was maintained at 5 cm and the syringe 
plunger was operated manually. Finally the resulting calcium-alginate-FDAE beads were 
allowed to cure in the medium for 10 min, then separated from the solution by filtration, rinsed 
with deionised water, and dried in a vacuum drying oven at 60 °C until a constant weight was 
obtained.  A schematic representation of the general production process is shown in figure 4.1. 
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Figure 4.1: A schematic representation of the production of alginate-FDAE beads (adapted from Egieyeh, 
2011 unpublished data). 
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4.3.3   Preparation of polymethylmethacrylate coated alginate extract (PMMA-alginate-
FDAE) of A. afra 
PMMA-alginate-FDAE was prepared by a modified water-in-oil-in-water (W1/O/W2) emulsion 
solvent evaporation method using water as internal aqueous phase(Tapas et al., 2011). First, 
sodium alginate (0.5 - 2.5% w/v) was dissolved in 3 ml water at 30 -35 °C by stirring with a 
magnetic stirrer for 20 minutes.  Then 200 mg of FDAE was added and the solution stirred for a 
further 20 min. The resulting mixture was drawn up in a 20 ml syringe and then added through a 
16 gauge needle to 20 ml solution of PMMA (4% w/v) in dichloromethane containing 1% v/v 
Span 80 and emulsified at 4000 rpm for 2 min in a homogenizer. The resulting W1/O primary 
emulsion was then added through a 16 gauge needle into 100 ml of water containing 1.25% v/v 
tween 80 and 2% w/v CaCl2 and emulsified at 850 rpm to form a W1/O/W2 emulsion. Stirring 
was continued for 1.5 hours with a mechanical stirrer to evaporate off the organic solvent. The 
resultant microcapsules were separated by decantation, washed thrice with water and then 
vacuum dried at 60 °C for 8 hours. The microcapsules were stored in a vacuum desiccator until 
used (Tapas et al., 2011). 
 
4.3.4 Determination of organoleptic and pharmaceutical properties of A. afra 
preparations 
In this study, certain organoleptic and pharmaceutical characteristics were chosen to be 
determined and compared viz, colour, taste, odour, texture,  particle size,  particle shape, 
moisture content,  aqueous solubility, entrapment efficiency of FDAE in modified forms, total 
flavonoid content of A. afra forms and release of flavonoids (FDAE) from modified A. afra 
forms. Recognizable changes in the organoleptic properties of a material may be an indication of 
changes in stability of the material. Unpleasant odours, tastes and smell of a material can be 
masked by addition of sweeteners, flavourants and aroma chemicals (Zheng and Keeney, 2006). 
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4.3.4.1 Determination of colour and odour of A. afra preparations 
The colour of the plant material preparations was determined by weighing and placing 100 mg of 
each untreated plant material preparation and against a white background. The colour observed 
against the white background was described. 
The British Pharmacopoeia 2000(BP., 2000b)method was used to determine the presence or 
absence of odour in the plant material preparations.  For this, 100 mg of each plant material 
preparation was weighed and placed on a watch glass about 10 cm in diameter. The material was 
allowed to stand for 15 minutes and then smelled to determine the presence or absence of any 
odour. 
 
4.3.4.2 Determination of particle size and shape of A. afra preparations 
Particle size and shape can affect the physico-chemical properties of a dosage form, bulk 
properties, product performance, processability, stability, bioavailability and appearance of the 
end product. These parameters also play a significant role in the homogeneity of dosage forms. 
The sieve and microscopic methods are the commonly used methods for determining particle 
size and shape. The method of the British Pharmacopoeia (BP., 2000b) was used in this study to 
determine the particle size grading of the A. afra preparations. 
Briefly sieves No’s 335, 180, 125 and 90 were used for the A. afra dried leaves and the FDAE 
while sieves No’s 1700, 1400, 1000 and 500 were used for the alginate and the PMMA-alginate 
beads of A. afra. The sieves were arranged in order of decreasing aperture size with a receiving 
pan closely fitted at the bottom. The assembled sets of sieves were mounted on a test sieve 
shaker (Figure 4.2). An accurately weighed amount (10 g) of the plant material preparation was 
placed onto the top-most sieve and the assembly shook for 20 minutes until sifting was 
practically complete. The retained powder on each sieve was collected, weighed and calculated 
as a percentage (w/w) of total feed. The degree of fineness of each feed was made according to 
the BP 2000 specifications. In this way, the plant materials could be described as being “coarse”, 
“moderately fine”, “fine’ or “very fine”. 
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The shape of the different plant material preparations was determined by microscopic 
examination.  For this, 5 mg of the FDAE, alginate-FDAE beads or PMMA-alginate-FDAE 
beads were sprinkled onto a microscopic slide and viewed under a light microscope “Nikkon 
Abbe 1.25” after which they were micrographed for their particle shapes. 
 
                                                    Figure 4.2: Mechanical test sieve shaker. 
 
4.3.4.3 Determination of moisture content of A. afra preparations 
When a substance is known to be hygroscopic, it is very critical and important to determine its 
moisture content  (EMEA, 1999). The method prescribed in the European Pharmacopoeia 4
th
 
edition 2002 (EP., 2002b)was used for the determination of the moisture content of the plant 
material preparations. This method was used to monitor the change in weight in plant material 
preparation resulting from any moisture loss. In this method, 0.3 g quantities each of the FDAE, 
alginate beads and PMMA- alginate beads of A. afra were separately weighed  in a flat bottom 
dish, dried in an oven for 3 hours at a temperature of 100 °C, allowed to cool for 10 minutes in a 
desiccator over anhydrous silica gel and the final weight recorded (EP., 2002b). The moisture 
content was calculated as a mass percentage using the following formulas; 
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Moisture weight= Initial weight (Before drying) – Final weight (After drying) -----Eqn. 4.1                        
Moisture content = (Moisture weight/ Initial weight) X 100% -----------------------Eqn. 4.2 
 
4.3.4.4 Determination of aqueous soluble fraction of A. afra preparations  
Solubility is an important property of a drug that determines the dissolution rate of the active 
ingredient. An active ingredient must be in the solution of gastric fluids, before it can be 
absorbed into the systemic circulation. Poor solubility and dissolution are undesirable properties 
of the active ingredient in oral solid dosage forms. In the case of the A. Afra preparations, the 
yield of extract obtained with distill water depends on the water-soluble matter present in the 
powder. 
In this study, the aqueous soluble fraction of the plant material preparations was determined at 
room temperature as follows: First, 0.2 g of plant material was accurately weighed in a 5 ml 
eppendorf tube, mixed with 2 ml of distilled water and vortexed for 1 minute and the mixture 
then kept at room temperature for 8 hours with additional vortexing after every hour. At the end 
of the extraction, the mixture was filtered under vacuum, the residue collected on a previously 
weighed filter paper, the residue plus filter paper oven dried at 35 °C for 4 hours and then left in 
open air for an hour to equilibrate at room temperature. The joint weight of dried filter paper and 
residue was noted and the weight of the filter paper subtracted to obtain the weight of the 
residue. The solubility or water extractable matter was then determined by subtracting the weight 
of the residue from the total plant material weight and expressing it as a percentage i.e. 
Solubility      = (Weight of initial plant material – Weight of dried residue) 
             Volume of solvent  
From the results obtained and the descriptive phrases provided in the BP 2000 (Table 4.1) the 
solubility of each plant material was then derived. 
 
 
 
X 100%- - - Eqn. 4.3 
 
 
 
 
39 
 
Table 4.1: Common descriptive phrases of solubility and the corresponding quantitative 
solubility ranges as per BP 2000. 
Descriptive phrase Approximate quantities of solvent by 
volume for 1 part of solute by weight 
Very soluble Less than 1 part 
Freely soluble From 1 to 10 parts 
Soluble From 10 to 30 parts 
Sparingly soluble From 30 to 100 parts 
Slightly soluble From 100 to 1000 parts 
Very slightly soluble From 1000 to 10, 000 parts 
Practically insoluble More than 10, 000 parts 
 
 
4.3.4.5 Evaluation of entrapment efficiency of FDAE in alginate beads and PMMA-alginate 
beads 
The alginate-FDAE and PMMA-alginate-FDAE beads were prepared as explained in sections 
4.3.2 and 4.3.3, respectively. Three samples (100 mg) each of the alginate and PMMA-alginate 
beads were weighed in 15 ml test tubes, 10 ml of simulated intestinal fluid (phosphate buffer 
solution pH6.8, without enzyme) added, and the mixture warmed at 37 °C and stirred overnight 
using a magnetic stirrer. Thereafter the mixture was allowed to settle for 30 minutes and 3 ml 
aliquots of the supernatant containing the extract drawn into a 5 ml syringe, filtered through a 
0.45 µm filter (with the first 0.5 ml filtrate discarded) and filtrate collected in an eppendorf tube. 
From each filtrate 200 µl was transferred to a microplate well and its absorbance measured at 
349 nm using a microplate reader.  A calibration curve of the 349 nm absorbance of solutions 
containing various amounts of dissolved FDAE in distilled water versus concentration was then 
established and used to determine the amount of FDAE released from the beads. 
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Finally, the amount of extract in the beads was compared to the expected amount and the 
entrapment efficiency calculated as: 
%EE    =     (AD/AE) * 100 ------- Eqn. 4.5 
Where EE = entrapment efficiency, 
AD=the determined amount of extract per gram of beads and, 
AE=the expected amount of extract per gram of beads.  
This was done for triplicate samples and the average %EE of FDAE for alginate-FDAE versus 
PMMA-alginate-FDAE beads compared. 
 
4.3.4.6 Determination of total flavonoid content of Artemisia afra preparations 
The total flavonoid content of the preparations was estimated using the aluminium chloride 
colorimetric method (Lamien-Meda et al., 2008, Hoerudin, 2004) with some modifications. 
Luteolin was used as the reference and a standard curve of known concentrations of luteolin was 
generated. A stock solution of luteolin was prepared by dissolving 2 mg of luteolin in 2 ml of 
50% ethanol in water (v/v). Standard working solutions of concentrations 2.5, 20, 50, 100, 200, 
and 250 µg/ml were made up by diluting aliquots of the stock solution and diluting with 50% 
ethanol to achieve the above mentioned concentrations. 
To a 15 ml test tube, 0.5 ml of each standard solution, 1.5 ml of 95% ethanol (v/v), 0.1 ml of 
10% aluminium chloride, 0.1 ml of 1M potassium acetate and 2.8 ml of distilled water were 
added and the mixture incubated at room temperature for 30 minutes. Thereafter, 200 µl of the 
reaction mixture was transferred to a 96 well plate and its absorbance determined at 349 nm 
using a microplate reader. The absorbance versus luteolin concentration data was inserted 
GraphPad™ Prism, the standard curve established and the latter used for the quantification of the 
total flavonoids in the A. afra samples. For the blank, the 10% aluminium chloride was 
substituted with an equivalent volume of distilled water.  
For the determination of the total flavonoid content in the A. afra preparations, 2.5 mg of each 
plant preparation were weighed in a 5 ml screw capped Kimax test tube, 0.5 ml of distilled water 
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added and the mixture vortexed for 3 minutes to dissolve and provide the unhydrolysed samples. 
For hydrolysed samples, 1 ml of 2M hydrochloric acid was added to the solution, heated in a 
water bath at 80 °C for 40 minutes, allowed to cool and 1ml of 2M sodium hydroxide solution 
added to neutralize the solution. Then the solutions were reacted with aluminium chloride as 
described above and the flavonoid concentration in each hydrolysed and unhydrolysed plant test 
sample determined from, the luteolin standard curve generated with GraphPad™ Prism. Finally, 
the average total flavonoid levels in 3 replicates of each A. afra preparation was determined and 
compared.  
 
4.3.4.7 Evaluation of the release characteristics of modifiedArtemisia afrapreparations 
The release study was performed on 200 mg of each of the Artemisia afra preparations in 
Simulated Gastric Fluid (HCl solution, pH 1.2, without enzyme) and Simulated Intestinal Fluid 
(phosphate buffer solution pH 6.8, without enzyme), prepared according to the United States 
Pharmacopoeia 29 (USP) (http://www.pharmacopeia.cn/v29240). 
Briefly, 20 ml volume of SIF or SGF was placed in a 50 ml beaker, covered and heated to 37 °C 
in a water bath while the temperature was monitored with a thermometer. When a constant 
temperature had been achieved, 200 mg samples (alginate-FDAE beads and PMMA-alginate-
FDAE beads) were added into the fluid and the mixture stirred with a magnetic bar. Samples of 
the fluid (1 ml) were withdrawn at 5, 10, 20, 30, 40, 50, 70 and 90 minutes and replaced with 
same volume of fresh fluid in order to maintain constant volume. The withdrawn samples were 
centrifuged, the supernatant collected and 200 µl of the supernatant placed in a 96 well plate. 
The FDAE content was determined by reading the absorbance of triplicate samples of each 
herbal preparation at 349 nm. To determine the amount of FDAE released, a calibration curve of 
the 349 nm absorbance values obtained for various concentrations (50-300 µg/ml) of FDAE in 
simulated intestinal fluid was established and used to quantitate the amount of FDAE in the 
samples obtained for the 2 other preparations. From the amount released at each time point, the 
cumulative amount of FDAE extract released versus time was generated, analysed by 
GraphPad™ Prism and the percentage release of FDAE at 30 minutes (T30) determined and 
compared for the alginate-FDAE and PMMA-alginate-FDAE beads in the different media.  
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To determine the mechanism of release of the extract (FDAE) from FDAE-alginate and PMMA-
alginate FDAE beads,a simple relationship which describes drug release from a simple swellable 
polymeric matrix derived by Peppas et al., was used. This relationship is given by the 
Korsmeyer-Peppas model which is given by: 
F = Kt
n
   ----------------Eqn. 4.6 
where F = the percentage fraction of extract released at time t, 
  K = the release rate constant incorporating the structural and geometric characteristics of 
the drug dosage form, 
  n = the release exponent indicative of the drug release mechanism. 
The n value is used to characterize differential release and the value of n characterizes the release 
mechanism of drug. 
 
4.3.5 Development and validation of HPLC method 
Luteolin was selected as a marker for the comparison of level of active compound in the different 
preparations of A. afra. The luteolin levels in FDAE, alginate-FDAE beads and PMMA-alginate-
FDAE beads were determined by HPLC using a reverse phase method. Separation was effected 
on a Phenomenex Luna C-18 column with 4 µm particle size and a column length of 250 x 4.60 
mm i.d; 5u. The mobile phase consisted of 0.1% formic acid aqueous solution (solvent A) and 
0.1% formic acid in acetonitrile (solvent B). The elution gradient was: 0-22 min 15%B; 22-27 
min 100%B; 27-33 min 15%B. The solvents were filtered and degassed by membrane filtration 
prior to use. The column temperature was kept at 25 °C, eluent pumped at flow rate of 0.8 
ml/min, 20 µl samples injected and the luteolin peaks detected at 350 nm. As internal standard 
morin was used, mainly because it has similar physicochemical properties to luteolin, is 
extracted in ethyl acetate and absorbs at the same wavelength as luteolin i.e. 350 nm.  
To validate the assay, the following parameters were determined: linearity, precision and 
accuracy, lowest limit of detection and lowest limit of quantification.  
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In performing the validation, stock solutions of luteolin and morin were prepared in 50 % 
methanol water and stored in a refrigerator at -80 °C until use. Standard solutions were prepared 
by diluting the luteolin stock solution in 50% methanol water to a concentration range of 4.3 – 26 
µg/ml and internal standard morin to obtain a concentration of 100 µg/ml. For the standard curve 
100 µl of morin was added to each luteolin standard solution and the ratios of luteolin: morin 
peak area versus luteolin concentration plotted. GraphPad™ Prism was used for the plotting of 
the standard curve and determination of curve linearity (R
2
) and concentration in the 
unknownsamples. The precision of the analytical method was determined by assaying 3 
replicates of the low, medium and high concentration standard solutions on three consecutive 
days and on each occasion the average, standard deviation and % relative standard deviation 
(RSD) calculated and compared. The accuracy of the method was determined from the mean 
concentrations obtained for the replicates and the percentage difference. The limit of detection 
(LOD) and quantitation (LOQ) for luteolin was determined using the response (peak area) with 
LOD being determined as the analyte concentration giving a response 3 times that of the noise 
level i.e. signal to noise ratio 3:1 and with mean baseline noise of 0.4 mAU and the LOQ as the 
lowest concentration where an accuracy better than 20% was achieved (Ruckert et al., 2004). 
Lastly the percentage bias was determined as the difference between the concentration measured 
and the prepared concentrations expressed as a percentage of the prepared concentration.  
 
4.3.6 Quantification of luteolin in the Artemisia afra preparations 
For the quantification, the HPLC assay was used and the FDAE, alginate-FDAE and PMMA-
alginate-FDAE were assayed in two ways, the acid-hydrolysed and unhydrolysed methods. The 
latter provides the level of free flavonoid and the former the level of total flavonoid.  
First, hydrolysed and unhydrolysed sample solutions of the A. afra plant preparations were 
prepared. For the unhydrolysed samples, 75 mg of each plant preparation was placed in labelled 
15 ml conical-shaped centrifuge tubes, 100 µl of morin (IS, 100 µg/ml) and 3 ml of aqueous 
methanol (50%) added and the solution vortex mixed for 1 minute. For the hydrolysed plant 
sample solution, 3 ml of acidic aqueous methanol (MeOH: 2NHCL 50:50) was added, the 
mixture heated in a water bath at 80 °C for 40 minutes and then cooled. To both hydrolysed and 
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unhydrolysed plant sample solutions, 5 ml ethyl acetate was added, the mixture vortex mixed for 
3 minutes and centrifuged for 15 minutes at 3500 rpm. Using a pipette, the ethyl acetate 
supernatant was transferred to a clean test tube and evaporated to dryness under a gentle stream 
of nitrogen gas. The residue was reconstituted in 1 ml of mobile phase solution (water: 
acetonitrile 50: 50), the mixture transferred to HPLC vials and 20 µl aliquots injected unto the 
HPLC column. From the chromatograms the peak areas for luteolin and internal standard peaks 
were obtained.  
To identify luteolin in the plant samples, the UV spectra and retention times obtained from the 
chromatograms of the plant samples were compared to that obtained with the pure luteolin 
standard solutions. Finally, the height of the luteolin peak was noted, the luteolin: internal 
standard peak area ratio calculated and the levels of free or total luteolin in each sample 
determined from the standard curve regression equation. Three replicates of each preparation 
were done and average values for the 3 plant materials compared using student’s t-test.  
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4.4 Results and discussion 
4.4.1  Preparation of plant materials 
The characteristics of the freeze dried aqueous extract (FDAE), alginate-FDAE and PMMA-
alginate-FDAE beads of A. afra prepared as described in sections 4.3.1, 4.3.2 and 4.3.4 are 
summarized in table 4.2. Three batches of the FDAE were prepared and the particle size of the 
leaves, the temperature of the solvent and the time duration for the extraction were constant for 
all extractions. The average yield for the freeze dried aqueous extract was 21.8% and this was 
similar to that obtained by previous investigators e.g. 19.9% by Komperlla (2005) and 21.96% 
by Dube (2006).  
The yields for the modified forms were slightly lower at 16.5% and 12.6% for alginate-FDAE 
beads and PMMA-alginate-FDAE beads respectively (Table 4.2). In the preparation of the 
FDAE, 2 g of dried leaves was calculated to be equivalent to 8 g of dried leaves used to produce 
one 150 ml cup of the traditional infusion. For the modified forms, 4 g of FDAE was used to 
prepare the alginate-FDAE and PMMA-alginate-FDAE beads. The increase in quantity of FDAE 
used to prepare the modified forms was to compensate for any subsequent leaching that may 
occur from the beads into the calcium chloride solution and dichloromethane for the alginate-
FDAE beads and PMMA-alginate-FDAE respectively. The small difference in yields seems to 
reflect  the FDAE entrapment efficiency in these modified forms (Table 4.2). 
 
4.4.2 Organoleptic and pharmaceutical properties of the FDAE, alginate-FDAE beads 
and PMMA-alginate-FDAE beads of Artemisiaafra 
A summary of the organoleptic and pharmaceutical properties of the A. afra forms is shown in 
table 4.2 and pictures of the FDAE, alginate-FDAE and PMMA-alginate-FDAE are given in 
figures 4.3, 4.4 and 4.5 respectively.  
 
 
 
 
 
 
 
46 
 
Table 4.2: Organoleptic and pharmaceutical properties of Artemisia afra forms. 
Test FDAE Alginate-FDAE PMMA-alginate-
FDAE 
Yield (%) 21.733 ±1.850 16.543 ± 0.039 12.613 ± 0.044 
Physical appearance Brittle, hygroscopic Small free flowing 
spherical beads 
Small free flowing 
spherical beads 
Colour Light brown Dark brown Brown 
Odour Aromatic Pungent Pungent 
Taste Bitter Bitter Bitter 
Particle size Coarse Not gradable Not gradable 
Moisture content (%) 10.68 ± 0.727 6.759 ± 0.151 8.034 ± 0.279 
Water soluble fraction 
(%) 
83.858 ± 1.753 7.494 ± 0.492 0.939 ± 0.440 
Entrapment efficiency(%) N/A 42.812 ± 0.979 37.603 ± 4.599 
Total flavonoid content in 
hydrolysed samples (µg 
LE/mg of extract) 
19.905 12.133 3.676 
Total flavonoid content in 
un-hydrolysed samples 
(µg LE/mg of extract) 
24.533 11.257 2.609 
Where LE = luteolin equivalent. 
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Figure 4.3: Photomicrograph of FDAE (4X). 
 
Figure 4.4: Photomicrograph of alginate-FDAE beads (4X). 
 
Figure 4.5: Photomicrograph of PMMA-Alginate-FDAE beads (4X). 
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The freeze dried aqueous extract of the Artemisia afra leaves were initially light brown in colour 
but rapidly changed to a dark brown colour because of its hygroscopicity. The alginate-FDAE 
beads were dark brown in colour unlike the PMMA-alginate-FDAE which was brown in colour. 
The dripping techniques used in the production of the beads produced spherical droplets which 
upon falling down into the calcium chloride solution resulted in spherical gel particles due to the 
ionic interactions between the alginate and the Ca
2+
 ions (Finotelli et al., 2010). The FDAE, 
alginate-FDAE and PMMA-alginate-FDAE had unpleasant odours and, taste and presence of 
such characteristics normally will result in poor patient acceptability of dosage form. However, 
such negative characteristics can be masked with excipients when the extracts are incorporated 
into a tablet or capsule form. 
4.4.2.1 Particle size and shape of Artemisia afra preparations 
Particle size and shape are crucial parameters worth considering in the manufacture of dosage 
forms in that they influence dissolution and bioavailability. Under the microscope, the FDAE 
particles appeared to be irregularly shaped while the alginate-FDAE and the PMMA-alginate-
FDAE beads appeared to have a fairly regular spherical shape (Figures 4.4, 4.5 and 4.6). The 
particle size distribution of the various preparations of A. afra is given in table 4.2, figure 4.6 and 
Appendix 3. According to the BP 2000 classification system, A. afra dried leaf powder and the 
freeze dried aqueous extract powder were both classified as coarse, with the FDAE appearing to 
be much finer than the A. afra dried leaves. The BP 2000 classification was also used to classify 
the size distribution of the modified forms. On this basis, the alginate-FDAE beads and the 
PMMA-alginate-FDAE which were seen to be non-uniform in particle size (due to the variation 
in the sizes of the beads obtained) were thus classified as not gradable (Table 4.2). The ranges in 
particle size seen with the modified forms may have an impact in dosage form preparation such 
as causing inconsistent weight and content of dosage form. An option to prevent this problem is 
the removal of all the bigger particles by additional sieving. Figure 4.6 shows the particle size 
range of the different A. afra plant preparations. 
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Figure 4.6: Particle size of A) A. afra dried leaves, B) FDAE of A. afra, C) Alginate beads and D) PMMA-
alginate beads measured using the sieve method. 
 
4.4.3 Moisture content of Artemisia afra preparations 
The percentage moisture content data for the FDAE, alginate beads and PMMA-alginate beads 
of A. afra is given in Appendix 4 and summarised in table 4.2. The average moisture content for 
FDAE, alginate-FDAE beads and PMMA-alginate-FDAE beads were 10.68 ± 0.73%, 6.76 ± 
0.15%, 8.03 ± 0.27% respectively. The FDAE is known to be hygroscopic, thereby explaining its 
higher moisture content compared to that of the other preparations. The moisture content of the 
modified preparations of the FDAE is low and this is an indication that they are less hygroscopic 
than the FDAE. The low moisture content observed in the modified forms could be due to the 
excipients added to the FDAE and the methods of preparation used to modify the FDAE into 
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beads. In addition, at room temperature, the physical appearance of the FDAE changed from a 
light brown powder to a sticky dark brown gum thus indicating that its moisture content 
increases with increasing storage hours. Unlike the FDAE, the physical appearance of the 
modified forms is stable on storage without any visible physical changes suggesting that they 
were reasonably non-hygroscopic. A full investigation on their hygroscopicity was however not 
done in this study. 
 
4.4.4 Aqueous soluble fraction of Artemisia afra preparations 
The results of the experiments to determine the aqueous solubilities obtained at room 
temperature for the FDAE, alginate-FDAE beads and PMMA-alginate-FDAE beads of A. afra 
are given in Appendix 5 and summarised in table 4.2. For oral solid dosage forms, aqueous 
solubility is a crucial factor influencing the bioavailability of drugs and the solubility of 
compounds may be described as per the description given in table 4.3. 
Table 4.3: Common descriptive phrases of solubility and the corresponding quantitative 
solubility ranges as per BP (2000). 
Description Approximate Weight Of Solvent (G) Necessary To 
Dissolve 1 G Of Solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble 1000 to 10,000 
Practically insoluble More than 10, 000 
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On average, 25.8 mg of the FDAE of A. afra was soluble in 1 ml of distilled water (Appendix 
5.1) thus indicating that 1000 mg of FDAE powder required approximately 38.7 ml of distilled 
water to dissolve and that the FDAE powder could be categorized as being sparingly soluble. For 
the alginate-FDAE beads of A. afra, 1000 mg of the beads required approximately 441 ml of 
distilled water to dissolve and therefore it could be classified as being slightly soluble in water. 
Lastly, for the PMMA-alginate-FDAE beads, 1000 mg of the beads required approximately 3529 
ml of distilled water to dissolve classifying it as being very slightly soluble. As expected the 2 
modified forms were less soluble in water than the FDAE, but even the aqueous extract of FDAE 
can only be classified as being sparingly soluble in water at room temperature. This suggests the 
traditional tea infusion method of preparing the FDAE (as was used in this study) resulted in a 
preparation containing additional solutes (and possibly active compounds) that are not fully 
soluble in water at room temperature. The method used to prepare extracts used to establish or 
evaluate the pharmacological effects of A. afra aqueous preparation can thus possibly be an 
important factor to keep in mind. 
 
4.4.5 Entrapment efficiency of FDAE in modified Artemisia afra preparations 
Entrapment efficiency is the ratio of the determined drug content in the formulation to the loaded 
amount (experimental drug content). The average entrapment efficiency of alginate-FDAE beads 
and PMMA-alginate-FDAE beads was 42.812% and 37.603% respectively (Tables 4.2 and 
Appendix 6).  At present, there is very little information on the entrapment efficiency of herbal 
material in alginate or polymethylmethacrylate preparations but EE% of 51.7% to 68.6% was 
found for curcumin in alginate beads (Song, 2012 #106).The loading efficiency of water soluble 
drugs in alginate beads is much lower than that of water insoluble drugs (Aslani and Kennedy, 
1996) and this is due to leakage of drugs from alginate beads having large gel porosity (Liu et al., 
1997). The low values obtained in this study may thus be the result of leaching of the water 
soluble FDAE extract from the beads into the calcium chloride solution. The drug entrapment 
efficiency is important in bead drug delivery systems because the actual amount of drug in the 
beads is what will be available for absorption (Ito et al., 2010). In all, the entrapment efficiency 
of the alginate-FDAE and PMMA-alginate-FDAE bead formulation was fair but may be 
improved.  
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4.4.6 Determination of total flavonoid content in the Artemisia afra preparations  
This experiment was done to determine the total flavonoid content (TFC) of the plant material 
using the aluminium chloride method. Luteolin was the standard used to establish the calibration 
curve (Figure 4.7), which was linear from 20 to 250 µg/ml (r
2 
= 0.9934). The total flavonoid 
content of the plant materials were expressed as luteolin equivalent (LE) per mg of extract and 
are shown in appendix 7and figure 4.8. 
 
Figure 4.7: Standard curve of luteolin concentration versus absorbance at 349 nm used for the quantification 
of the total flavonoid content in the different A. afra preparations (r
2 
= 0.9934; slope = 0.0007 ± 
0.0559). 
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Figure 4.8: The total flavonoid content (µg LE/mg) of the hydrolysed and unhydrolysed extracts of A. afra 
plant preparations. The P values are for the t-test of TFC in hydrolysed vs. unhydrolysed plant 
preparations. 
Flavonoids are one of the most widespread and diverse group of natural phenolic compounds. 
The flavonoids in the A. afra plant combined with aluminium to form a complex flavonoid-
aluminium that could be measured. Using the standard curve generated for luteolin (r
2 
= 0.9934), 
the total flavonoid content of the various A. afra preparations (µg of LE/mg of A. afra plant 
preparation) was found to vary from 3.67 µg/mg in hydrolysed PMMA-alginate-FDAE beads, 
12.133 µg/mg of hydrolysed alginate-FDAE beads to 24.5 µg/mg in hydrolysed FDAE. 
When the FDAE of A. afra plant was subjected to acid hydrolysis, the level of TFC was 
significantly increased compared to the level in the unhydrolysed FDAE (t-test pFDAE = 0.0482). 
However, when the modified preparations were subjected to hydrolysis the levels of TFC in both 
preparations were relatively similar as compared to the unhydrolysed preparations (i.e. t-test 
palg.beads = 0.223 and ppmma-alg. = 0.352). Compared to the FDAE, the 2 modified products thus 
contained very little acid hydrolysable (i.e. conjugated) flavonoids.  Plant preparations normally 
contain several different flavonoids. The increase in total flavonoid content observed after acid-
hydrolysis can be explained by the fact that glycosides (and other conjugates) present in the plant 
preparations, broke down to produce flavonoid aglycones that were able to form complexes with 
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aluminium chloride by binding at the hydroxy-oxo- and ortho-hydroxy-oxo-groups (Smirnova 
and Pervykh, 1998).  The FDAE thus had a fair proportion of its flavonoid content in this 
glycoside (or conjugate) form but not the modified preparations. The latter contained more of its 
flavonoids in aglycone form. 
Many investigators determined the total flavonoid content in foods and plants using the 
aluminium chloride method used in this study. Meda et al., (2004) were able to determine the 
TFC in Burkina Faso honey using this method and they reported that the method was only 
specific for flavanols and flavones and thus did not represent the real total flavonoid content. 
Thus in this study, a high performance liquid chromatography method was used to quantify 
luteolin in the A. afra plant preparations. 
The % entrapment efficiencies of 42.8% and 38.6% for alginate-FDAE and PMMA-alginate-
FDAE are reflected in the total flavonoid content of these forms. From the TFC (µg of 
luteolin/mg of bead) values, it can be calculated that to formulate a 250 mg capsule containing 
alginate-FDAE or PMMA-alginate-FDAE, each will contain approximately 3 mg and 0.9 mg of 
luteolin respectively. These values of active herbal ingredient (AHI) seem insufficient and 
impractical to be formulated into a herbal medicine dosage form expected to produce a 
therapeutic response. Thus the loading of active herbal ingredient (sufficient to produce a 
therapeutic effect) into the plant product is of great importance and suggests that modified forms 
should be prepared in a manner in which they contain a higher load of active ingredient per mg 
of material. 
 
4.4.7 Release of FDAE from modified Artemisia afra preparations in gastrointestinal 
fluids 
Multi-unit controlled release dosage forms pass via the gut in a manner that avoids the gastric 
emptying and different transit rates (Breimer, 1980) and release drugs more uniformly in a 
predictable manner (Follonier and Doelkar, 1992). Consequently, much research efforts has been 
concentrated on the development of micro particles using natural polymers as they are derived 
from natural sources, do not require organic solvent during manufacture, is readily available and 
qualified for a number of chemical modifications (Vyas and Khar, 2002). One objective of this 
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study was to use alginate and polymethylmethacrylate to produce beads containing the freeze 
dried aqueous extract as active herbal ingredient that will be released slower and more uniformly 
when taken orally.  
Consequently, the in vitro release of FDAE from alginate-FDAE and PMMA-alginate-FDAE 
beads in simulated gastric fluid and simulated intestinal fluid was investigated and the release 
characteristics of the FDAE from the modified preparations obtained is shown in figure 4.9. 
 
Figure 4.9: The percentage release profiles of FDAE from (A) alginate-FDAE beads and (B) PMMA-alginate-
FDAE beads in SIF and SGF determined using UV at 349 nm. 
 
At 30 minutes at pH 1.2, alginate-FDAE released 32.780% of FDAE and PMMA-alginate-FDAE 
released 76.297% of FDAE (Table 4.5) whileat 30 minutes at pH 6.8, alginate-FDAE released 
88.718% of FDAE and PMMA-alginate-FDAE released 93.518% of FDAE (Table 4.5).  
For both the alginate-FDAE and PMMA-alginate-FDAE rapid release of FDAE occurs at pH 6.8 
whereas only 32.780% of FDAE is released from alginate-FDAE and 76.297% of FDAE 
released from PMMA-alginate-FDAE atpH 1.2 respectively. The faster and more extensive 
FDAE release in SIF could possibly be due to the fact that the beads swelled and eventually burst 
giving rise to the increase in the release of extract. Similar rapid release of water soluble drugs 
from alginate beads at higher pH have been reported (El-Kamel et al., 2003) and this has been 
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considered as a major problem in sustaining drug release in SIF. Previous data has shown that 
alginate beads swell less at pH 1.2 thus slow penetration of SGF into the almost unswelled beads. 
The slow penetration together with complex drug release mechanisms involving displacement of 
drug from alginate by the counter ions present in the medium and subsequent diffusion of the 
free drug out of the beads were responsible for the slow release of the drug from alginate beads 
in SGF (Halder et al., 2005). This therefore suggests that in the stomach (at low pH), minimum 
release of FDAE (active herbal ingredient) from the beads will be achieved while in the 
intestines at higher pH maximum release of FDAE will be effected from the beads. 
The alginate-FDAE and PMMA-alginate-FDAE beads alone do not seem suitable as oral 
controlled release dosage forms.  Some studies have shown that the incorporation of resinate to 
the alginate beads appeared to extend drug release up to 6 hours although the major portion 
(90%) of the drug was released in 1.5 hours (Ray et al., 2008), thus the resin alginate beads 
provided marginal improvement in prolonging drug release in SIF. In conclusion, a pH 
responsive release profile displayed by the alginate-FDAE and PMMA-alginate-FDAE beads 
was observed, with faster release observed at a higher pH in SIF (6.8) compared to SGF (1.2) 
(Figure 4.9). The release can however be extended over a longer period by the incorporation of 
resinate to the beads containing the active herbal ingredient to obtain a more controlled release. 
To ascertain the release mechanism of the extract from FDAE-alginate and PMMA-alginate 
FDAE beads in SIF and SGF (i.e. obtain the n value describing the release mechanism as given 
in table 4.4), the data obtained from the in vitro release experiment was fitted to the Korsmeyer 
and Peppas model (Korsmeyer et al., 1983, Hayashi et al., 2005). The values of n obtained (for 
alginate-FDAE and PMMA-alginate-FDAE beads) were less than 0.5 in both SGF and SIF as 
shown in table 4.5. This indicated that the release from both modified forms was predominantly 
by classical Fickian diffusion. Thus the n values of > 0.5 obtained had no relevant significance in 
the release pattern observed for alginate-FDAE and PMMA-alginate-FDAE in both SIF and 
SGF. For this study, it was observed that the addition of alginate and polymethylmethacrylate, 
reduced the swelling and erosion of beads thus facilitating drug release by Fickian diffusion. 
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Table 4.4: Release exponent and equivalent release mechanism. 
Release exponent (n) Overall release 
mechanism 
Rate as a function of time 
<0.5 Fickian diffusion t
-0.5 
0.45 < n < 0.89 Non- Fickian diffusion t
n-1 
0.89 Case II transport Zero order release 
>0.89 Super case II transport t
n-1 
 
Table 4.5: Parameters of release and goodness of fit to Korsmeyer- Peppas model. 
 A. afra preparation Release 
rate (T30) 
% 
Korsmeyer-Peppas model 
Release exponent, 
n (Mean ± SD) n = 
2 
Regression 
coefficient, r
2 
SIF Alginate-FDAE beads 88.718 0.367 ± 0.026 0.94125 
PMMA-alginate-FDAE 
beads 
93.518 0.232 ± 0.019 0.9327 
SGF Alginate-FDAE beads 32.780 0.136 ± 0.039 0.9648 
PMMA-alginate- FDAE 
beads 
76.297 0.202 ± 0.019 0.9362 
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4.4.8 Development and validation of the HPLC assay 
A reverse phase HPLC method using morin as an internal standard was developed for the 
quantitation of luteolin in different preparations of A. afra. 
Under the HPLC conditions described in section 4.3.5, good symmetrical peaks with retention 
times of 13.87 ± 0.05 and14.31 ± 0.03 min were found for morin and luteolin respectively 
(Figures 4.10 and 4.11). The standard curve of peak height ratio versus luteolin concentration 
was linear (r
2
= 0.9917) over the concentration range of 4.3 to 26 µg/ml (Figure 4.12) and, 
described by the equation Y = 0.1354X ± 0.2076 (where Y= peak height ratio, X = luteolin 
concentration in µg/ml). The salient parameters for the validated assay are shown in table 4.6. 
 
Figure 4.10: HPLC chromatogram for the luteolin reference standard and morin (internal standard) at 370 
nm. Insert: UV/V is spectrum for the reference compound at 14.3 min (indicated in red on 
chromatogram). 
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Figure 4.11: Representative HPLC chromatogram of morin (peak M) at retention time 13.9 and luteolin 
(peak L) at retention time 14.3. 
 
 
Figure 4.12: Luteolin standard curve used in the quantitation of luteolin in Artemisia afra plant preparations 
by HPLC assay. Linear regression equation: Y = 0.1354X ± 0.2076; r
2
= 0.9917. 
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Table 4.6: Assay validation parameters for luteolin quantification in Artemisia afra 
preparations 
 
 
 
 
 
 
The results of the inter-day and intra-day accuracy and precision of the assay are shown in 
appendix 8.1. The limit of detection was found to be 22.4 ng on column, from an injected volum 
of 20 µl with a corresponding concentration of 1.3 µg/ml (Appendix 8.2) . The concentration of 
4.3 µg/ml had accuracy greater than 20% and was therefore considered to be the limit of 
quantitation (LOQ) for the assay. The average inter-day precision was found to be 4.895 ± 
1.421%. In this study, the absorbance of luteolin was read at 350 nm which differed slightly from 
the 349 nm  maximum wavelength for luteolin recommended by Markham (Markham, 1982). 
Overrall, these values indicated good validity and reproducibility of the assay. 
 
4.4.8.1 Identification and level of luteolin in Artemisia afra preparations 
The above described validated HPLC assay was used to identify and quantitate the levels of 
luteolin in the unhydrolysed and hydrolysed A. afra plant preparations. The hydrolysed and 
unhydrolysed samples of plant extracts were analysed and representative chromatograms 
obtained for each plant are given in figures 4.13 to 4.18. 
Validation parameters Luteolin Assay 
Retention time of luteolin (min) 14.3 
Linearity-Regression of coefficient (R
2
) 0.9917 
Inter-assay precision (RSD in 3 days) (%) 4.895 
LOD(ng on column) 22.4  
LOQ (µg/ml) 4.3  
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Figure 4.13: Representative HPLC chromatogram of unhydrolysed FDAE of A. afra. The retention time of 
morin (peak M) is 13.9 and luteolin (peak L) is 14.3. 
 
 
Figure 4.14: Representative HPLC chromatogram of hydrolysed FDAE of A. afra. The retention time of 
morin (peak M) is 13.9 and luteolin (peak L) is 14.3. 
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Figure 4.15: Representative HPLC chromatogram of unhydrolysed PMMA-alginate-FDAE of A. afra. The 
retention time of morin (peak M) is 13.9 and luteolin (peak L) is 14.3. 
 
 
Figure 4.16: Representative HPLC chromatogram of hydrolysed PMMA-alginate-FDAE of A. afra. The 
retention time of morin (peak M) is 13.9 and luteolin (peak L) is 14.3 
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Figure 4.17: Representative HPLC chromatogram of unhydrolysed alginate-FDAE of A. afra. The retention 
time of morin (peak M) is 13.9 and luteolin (peak L) is 14.3. 
 
 
Figure 4.18: Representative HPLC chromatogram of hydrolysed PMMA-alginate-FDAE of A. afra. The 
retention time of morin (peak M) is 13.9 and luteolin (peak L) is 14.3. 
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Table 4.7: Level of luteolin in the Artemisia afra plant preparations 
Plant samples Luteolin concentration (µg/mg of 
plant extract) Mean ± SD (n=3) 
Conjugated luteolin (%) 
Free luteolin Total luteolin 
FDAE 0.185 ± 0.24 0.235 ± 0.026 21 
Alginate-FDAE  0.067 ± 0.014 0.079 ± 0.093 15 
PMMA-alginate-
FDAE 
0.012 ± 0.0710 0.058 ± 0.082 79.3 
 
The FDAE, alginate-FDAE and PMMA-alginate-FDAE beads contained 0.185 ± 0.24, 0.012 ± 
0.071 and 0.067 ± 0.014 µg free luteolin/mg, and 0.235 ± 0.026, 0.079 ± 0.093 and 0.058 ±0.082 
µg total luteolin/mg, respectively (Table 4.7). As expected, the FDAE contained three to four 
times more luteolin than the modified forms. The alginate-FDAE contained more luteolin than 
the PMMA-alginate-FDAE but not significantly so (t-test p = 0.216), indicating that the former 
had more aglycones than the later. After the acid- hydrolysis, the levels of luteolin were 
increased in all the A. afra preparations of (Table 4.7).When the PMMA-alginate-FDAE was 
subjected to acid hydrolysis, the level of total luteolin was significantly increased compared to 
the free luteolin level (t-test p= 0.0412). This suggested that PMMA-alginate-FDAE had a 
substantial greater percentage of glycosides (79.3%) than FDAE and alginate-FDAE (21% and 
15%), meaning that although it has a lower load of luteolin it has more of the conjugated form. 
Compared to the PMMA-alginate-FDAE, the 2 other products thus contained very little acid 
hydrolysable (i.e. conjugated) flavonoids (Table 4.7). These differences in luteolin concentration 
were clearly associated with the methods of preparation for the various forms of A. afra. For the 
FDAE, extraction and freeze drying was involved whereby the constituents of the leaves were 
concentrated into a given small dry mass having a relatively high concentration of luteolin. For 
the modified forms, that same FDAE was dispersed in calcium chloride solution or 
dichloromethane and mixed (i.e. diluted) with alginate or polymethylmethacrylate and subjected 
to emulsification to form the alginate-FDAE and PMMA-alginate-FDAE beads respectively. In 
these processes, deterioration of flavonoids and/or complex formation between flavonoids and 
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the many constituents present in the plant extract and/or added excipients very likely occurred 
reducing the levels of detectable luteolin, as seen in the results obtained. 
The data therefore suggests that for the modified forms to contain luteolin in a more detectable 
form, they should be prepared in a manner in which they contain a higher load of active 
ingredient per mg of material. 
 
4.5 Conclusion 
The chapter addressed certain objectives of the study, viz, the preparation of the freeze dried 
aqueous extract (FDAE) and its modified forms, comparison of the organoleptic and 
pharmaceutical characteristics viztotal flavonoid (specifically luteolin levels) of the different 
forms of A. afra and evaluationof the release characteristics of FDAE of Artemisia afrafrom the 
alginate-FDAE and PMMA-alginate-FDAE beads in gastrointestinal fluids. 
From the results obtained the following conclusions could be drawn; 
Moderate to good yields of 21.8%, 16.5% and 12.6% was obtained for FDAE, alginate-FDAE 
and PMMA-alginate-FDAE beads respectively. The FDAE powder was coarse and irregularly 
shaped while the modified forms were not gradable and were both spherical in shape. The 
modification of FDAE into alginate-FDAE and PMMA-alginate-FDAE beads reduced porosity 
and this may lead to improved flowability when preparing dosage forms. The FDAE was 
confirmed to be hygroscopic while the modified forms less so. Modification to alginate-FDAE 
and PMMA-alginate-FDAE thus appeared to solve the problem of hygroscopicity. 
It was possible to load moderate amounts (37 - 42%) of FDAE into the bead forms suggesting 
that a reasonable amount of FDAE can be delivered via these forms. In addition the alginate-
FDAE and PMMA-alginate-FDAE showed similar FDAE release patterns of faster release at 
intestinal fluid than gastric fluid. Both are thus expected to predominantly release the actives in 
the intestine. The EE% of the modified forms related to the total flavonoid content (TFC) in that 
alginate-FDAE contained more luteolin per mg of material than PMMA-alginate-FDAE. 
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Finally, the FDAE contained higher levels of total and free luteolin than the modified forms, 
with relatively low values of total and free luteolin observed in the modified forms. However, the 
PMMA-alginate-FDAE showed a greater percentage of conjugated luteolin than the other forms. 
These differences in luteolin concentration could be attributed to the methods used in preparing 
the various forms of A. afra.  
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Chapter 5 
Determination of the in vitrointestinal permeability of luteolin from 
Artemisia afra preparations 
 
5.1 Introduction 
The work reported in this chapter aimed at investigating the absorption and gastrointestinal 
permeability of luteolin from the different preparations of A. afra prepared as discussed in 
chapter 4. To address this goal, the single-pass intestinal perfusion method was used and this 
method along with the other accompanying procedures used and the results obtained are 
presented and discussed. 
 
5.2 Materials and methods 
5.2.1 Reagents and equipment 
Luteolin was purchased from Sigma Aldrich (St Louis, USA), sodium pentobarbitone 6% from 
Kryon Lab (Pty) Ltd (South Africa) and phenol red from Merck (Germany). Acetonitrile, formic 
acid and methanol were HPLC grade and obtained from Merck (Germany). Double distilled 
waterproduced with Millipore filtration system was used during the entire HPLC procedure. 
Surgical equipments were supplied by Lasec (Pty) Ltd, South Africa. All other materials and 
reagents were either of analytical grade or of the highest purity and used as received. 
 
5.2.2 Animals 
Healthy male rats, weighing 250-350 g were purchased from the Animal Unit at the University 
of Stellenbosch, South Africa and were housed at room temperature in a well-ventilated animal 
room with free access to food and water. The lighting in the animal room was regulated to 
reproduce a 12-hr cycle of day and night conditions. Before the intestinal perfusion experiment, 
all animals were placed in cages and fasted for 12 hours with free access to tap water. For the 
experiment, the rats were anaesthetized with an intraperitoneal injection of pentobarbitone 
solution (40 mg/kg body weight), restrained in a supine position and then placed on a 37 ˚C 
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heating pad under a heating lamp during surgery throughout the in situ intestinal perfusion. The 
protocol for this study was approved by the University of the Western Cape Senate Research 
Ethics Committee (Registration no. 12/7/4, Appendix 1). 
 
5.2.3 Surgical procedures 
The surgical protocol used in the study was similar to that described elsewhere (Dang et al., 
2012, Singhal et al., 1998, Cummins et al., 2003, Zhang et al., 2006), with minor modifications. 
 
 
 
 
Figure 5.1: Illustration of single pass rat intestine perfusion model set up (modified from Cummins et al., 
2003).Note: In the experiments for the data reported, only the ileum was cannulated. 
 
A 5-cm-long midline incision into the abdomen was performed on the anaesthetized animal, the 
intestines located and the ileal segment carefully isolated for perfusion. Care was taken to handle 
the small intestine gently in order to maintain an intact blood supply. Using surgical scissors, 
incisions were made at both ends of the isolated intestinal segment. Glass cannulas (2 cm long, 4 
mm o.d. (outside diameter)) connected to tubing (6mm o.d.) were inserted at both ends (at inlet 
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cannula to infuse and at outlet cannula to collect perfusion fluids). At the inlet side, syringe filled 
with pre-warmed saline was connected to gently flush the intestine so that intestinal content 
exited at outlet cannula. A syringe pump was then connected to the inlet cannula and pre-warmed 
normal saline (blank perfusate vehicle) infused into the segment at rate of 0.25 ml/min to test the 
free flow through the segment at the outlet. The isolated intestine was then reinserted into the 
abdominal cavity, the cut abdominal wall partially stitched closed and the closed abdominal area 
covered with moist pad of surgical gauze. The isolated intestine model was now ready for 
perfusion. The experimental set up was performed as illustrated in figures 5.1 and 5.2. 
 
 
 
Figure 5.2: Cannulated intestinal segment of Wistar rat prior to reinsertion into abdominal cavity. 
 
 
5.2.4 Single-pass intestinal perfusion 
The perfusion vehicle was normal saline. All perfusion solutions contained 20 µg/ml phenol red 
to act as a non-absorbable marker for measuring water flux and to correct for changes in the 
water flux across the intestine (Sutton et al., 2001). Solutions containing 20 μg/ml of luteolin in 
pure form, and 5 μg/ml of luteolin in FDAE, 2.5μg/ml of luteolin in alginate-FDAE and 2.3 
μg/ml of luteolin in PMMA-alginate-FDAE in saline were infused into the rat ileum. The in 
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situintestinal infusions were initiated by infusing the test solution at 1 ml/min for 2 min to ensure 
filling the segment rapidly , followed by perfusion at 0.25 ml/min for the remainder of the 
experiment (i.e. 50-60 min) (Mukinda, 2010). Samples of the intestinal outflow were 
continuously collected into pre-weighed vials over 10 min intervals for up to 60 min. The 
collected perfusate samples were kept on ice until the end of the study where after they 
wereimmediately frozen and stored at -80 °C until analysis. At the end of the experiment, the 
length of the segment of cannulated intestine from the end of the inlet cannula to the beginning 
of the exit cannula was measured without stretching it, and then the animal was sacrificed by 
performing bilateral thoracotomy. 
 
5.2.5 Quantitation of phenol red for water flux measurement 
To correct for volume changes due to changes in the water flux across the intestine, phenol red 
was added to all perfusion solutions at a concentration of 20 µg/ml (Sutton et al., 2001). The 
quantitation of phenol red in the perfusate samples was performed using high performance liquid 
chromatography (HPLC) and an external phenol red calibration curve obtained for standard 
solutions of 1 and 50µg/ml phenol red in normal saline (linear regression R
2
 =0.9978). 
 
5.2.6 HPLC assay of luteolin in plant sample perfusate 
For the assay of luteolin in the plant perfusatesamples, the stored frozen samples were thawed, 
and then extracted, either as such or after acid hydrolysis, into ethyl acetate (which is then 
evaporated to dryness and the residues used) for the quantitation of the free and total luteolin 
levels in the samples. The validated assay reported in section 4.4.8 was used. 
All samples were analysed by HPLC (Agilent HPLC system-1200 series). The optimum 
separation of the test compounds (i.e. luteolin and phenol red) was achieved with a mobile phase 
composed of 0.1% formic acid aqueous solution (solvent A) and 0.1% formic acid in acetonitrile 
(solvent B), flowing through a Phenomenex Luna column (5 µm, 4.6 x 250 mm) at a flow rate of 
0.8 ml/min and at 25 °C with UV detection at 350 nm. The elution gradient was: 0-22 min 
15%B; 22-27 min 100%B; 27-33 min 15%B. The volume of samples injected was 20 µl for all 
perfusate samples and the run time was 33 min.  
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5.2.7 Data analysis 
The permeabilities of luteolin and luteolin in A. afra plant preparations i.e. FDAE, alginate-
FDAE beads and PMMA-alginate-FDAE beads across the rat intestine were calculated based on 
the disappearance of the parent compound (luteolin) from the lumen (Plumen) using equation 1 
(Singhal et al., 1998; Cummins et al., 2003).  
 
Plumen=-Q/2πrLxIn(Clumen/C0)(1) 
 
Where, r = radius of the intestinal lumen (0.3cm) 
  L = length of the segment (cm),  
 Q = flow rate of treatment through the intestine (0.25ml/min),  
            C0 = concentration of the test compound at the start of the perfusion (in syringe,   μg/ml),  
 Clumen = steady-state concentration of the test compound exiting the lumen (µg/ml). 
 
The concentrations of luteolin in the perfusate were corrected for changes in the water flux at 
each time interval using equation (2): 
 
Conc corrected = Conc measured x [phenol red]in/[phenol red]out(2) 
 
Graphs of total or free luteolin concentration (µg/ml) were plotted against time. Student t-test 
was used to compare differences and data presented as mean ± SD. Statistical significance was 
set at p≤0.05. 
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5.3 Results and discussion 
5.3.1 Absorption of luteolin from Artemisia afra preparations in the rat single-pass 
intestinal perfusion model 
To assess the effect alginate and PMMA-alginate modifications has on the absorption of luteolin 
(total and free) contained in solutions of pure luteolin, and A. afrapreparations i.e.(FDAE, 
alginate-FDAE, PMMA-alginate-FDAE), solutions were individually perfused through a 
segment of the rat intestine in the absence of gut contents. The HPLC validated assay developed 
in section 4.4.8 was used for the simultaneous quantitation of luteolin and phenol red in the in 
situ perfusate samples. Before analysis, the latter were either un-hydrolysed or acid-hydrolysed 
to quantitate the free and total luteolin levels in the samples. 
Under the HPLC conditions described in section 5.2.5, good symmetrical peaks with retention 
times of 11.52 ± 0.06 min and 13.81 ± 0.03 min was found for phenol red and luteolin 
respectively (Figure 5.3 and Appendix 9). 
 
 
Figure 5.3:  A representative HPLC chromatogram of in situ perfusion samples containing luteolin and 
phenol red at 350 nm. The retention time of luteolin is 13.8 while that for phenol red is 11.4. 
Profile of total and free luteolin content of perfusate samples collected at different time points is 
shown in figures 5.4 and 5.5 and tables 5.1 and 5.2. 
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Figure 5.4: Profiles of A) total luteolin content and B) free luteolin content in effluent perfusate samples as a 
function of time.The rat intestine segment was perfused with saline solutions containing 20 µg/ml 
pure luteolin, FDAE containing 5 µg/ml of luteolin, alginate-FDAE containing 2.5 µg/ml of 
luteolin and PMMA-alginate-FDAE containing 2.3 µg/ml of luteolin. Luteolin content is expressed 
as µg/ml and the curves represent mean values of three datasets i.e. n =3. 
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Figure 5.5: Profiles of free and total luteolin concentrations versus time following perfusion with A) pure 
luteolin B) FDAE C) alginate-FDAE D) PMMA-alginate-PMMA. The rat intestine segment was 
perfused with saline solutions containing 20 µg/ml pure luteolin, FDAE containing 5 µg/ml of 
luteolin, alginate-FDAE containing 2.5 µg/ml of luteolin and PMMA-alginate-FDAE containing 
2.3 µg/ml of luteolin. Luteolin content is expressed as µg/ml and the curves represent mean values 
of three datasets i.e. n =3. 
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Table 5.1: Total luteolin content in rat intestinal perfusate at various time intervals during 
perfusions with pure luteolin and A. afra forms. 
Time interval 
(min) 
Total luteolin perfusate concentrations (Mean ± SD (µg/ml)) after  perfusions with 
Luteolin (pure) 
(*Cin = 20 µg/ml) 
 
FDAE 
(*Cin = 5 µg/ml) 
 
alginate-FDAE 
(*Cin = 2.5 µg/ml) 
 
PMMA-alginate-FDAE 
(*Cin = 2.3 µg/ml) 
 
0-5 15.55 ± 0.13 3.223 ± 0.07 1.329 ± 0.04 1.05 ± 0.17 
5-10 17.70 ± 0.03 3.481 ± 0.05 1.579 ± 0.17 1.234 ± 0.18 
10-20 18.78 ± 0.02 3.824 ± 0.32 1.678 ± 0.14 1.247 ± 0.36 
20-30 18.91 ± 0.06 3.875 ± 0.30 1.501 ± 0.26 1.2370 ± 0.11 
40-50 18.76 ± 0.04 3.721 ± 0.28 1.464 ± 0.20 1.215 ± 0.22 
50-60 18.61 ± 0.07 3.946 ± 0.15 1.460 ± 0.05 1.218 ± 0.16 
R10-60 18.05 ± 0.05 3.678 ± 0.20 1.501 ± 0.14 1.200 ± 0.20 
 
Total luteolin content as mean ± SD (n =3). Each value represents the total luteolin content of perfusate at 
various time points. R10-60 = average of the steady-state data (samples obtained between 10 and 60 min).  
 
 
Table 5.2: Free luteolin content in rat intestinal perfusate at various time intervals during 
perfusions with pure luteolin and A. afra forms. 
Time interval (min) Free luteolin perfusate concentrations (Mean ± SD (µg/ml)) after  perfusions with 
 
Luteolin (pure) 
(*Cin = 20 µg/ml) 
 
FDAE 
(*Cin = 5 µg/ml) 
 
alginate-FDAE 
(*Cin = 2.5 µg/ml) 
 
PMMA-alginate-
FDAE 
(*Cin = 2.3 µg/ml) 
 
0-5 14.981 ± 0.13 2.417 ± 0.29 1.213 ± 0.38 0.89 ± 0.33 
5-10 16.997 ± 0.08 2.738 ± 0.24 1.320 ± 0.38 1.095 ± 0.35 
10-20 18.589 ± 0.18 3.456 ± 0.27 1.425 ± 0.44 1.175 ± 0.42 
20-30 18.908 ± 0.11 3.410 ± 0.22 1.398 ± 0.30 1.140 ± 0.35 
40-50 18.789 ± 0.14 3.360 ± 0.15 1.415 ± 0.21 1.114 ± 0.31 
50-60 17.958 ± 0.12 3.392 ± 0.25 1.409 ± 0.26 1.115 ± 0.22 
R10-60 17.647± 0.13 3.127 ± 0.24 1.363 ± 0.33 1.088 ± 0.33 
 
Free luteolin content as mean ± SD (n =3). Each value represents the free luteolin content of perfusate at 
various time points. R10-60 = average of the steady-state data (samples obtained between 10 and 60 min).  
 
 
From the results obtained, insight into the amounts and form of luteolin present in the perfusate 
samples over the perfusion period can be gained. Generally, it was observed that the 
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disappearance of luteolin from each plant preparation was relatively steady after 10 min 
perfusion. The luteolin content disappearing from pure solution at steady state was relatively low 
(῀12%), as can be seen from the total and free luteolin concentrations in perfusate samples at 
steady state (Tables 5.1 and 5.2) when compared to that of the A. afra forms.This indicated that 
not much was disappearing from pure luteolin, indicating poor uptake (permeability) than the 
plant forms. 
 
Table 5.3: Total luteolin content uptake at various time intervals from perfusions of pure 
luteolin and A. afra forms. 
Time interval 
(min) 
Effective permeability (Peff) values of total luteolin  (cm/s) 
Luteolin (pure) 
 
FDAE 
 
 
alginate-FDAE PMMA-alginate-FDAE 
 
0-5 0.0106 0.0343 0.0250 0.0305 
5-10 0.0110 0.0335 0.0309 0.0298 
10-20 0.0115 0.0327 0.0301 0.0280 
20-30 0.0123 0.0324 0.0296 0.0279 
40-50 0.0131 0.0289 0.0325 0.0318 
50-60 0.0147 0.0289 0.02980 0.0260 
R10-60 0.0122 0.0318 0.0294 0.029 
 
 
Table 5.4: Free luteolin content uptake at various time intervals from perfusions of pure 
luteolin and A. afra forms. 
Time interval 
(min) 
Effective permeability (Peff) values of free luteolin   (cm/s) 
Luteolin (pure) 
 
FDAE 
 
 
alginate-FDAE PMMA-alginate-FDAE 
 
0-5 0.0103 0.0335 0.0323 0.0257 
5-10 0.0140 0.0331 0.0309 0.0262 
10-20 0.0110 0.0317 0.0291 0.0276 
20-30 0.0113 0.0312 0.0295 0.0276 
40-50 0.0121 0.0285 0.0317 0.0290 
50-60 0.0131 0.0281 0.0295 0.0307 
R10-60 0.0119 0.0310 0.0299 0.0278 
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Table 5.5: Statistical parameters of total and free luteolin uptake from perfusions of pure 
luteolin and A. afra preparations. 
Sample Luteolin 
uptake 
p value, (T-test result for total vs free 
luteolin uptake in A. afra 
preparations) 
Luteolin vs FDAE total 0.0022, S 
free 
0.0022, S 
FDAE vs alginate- FDAE total 0.5887, NS 
free 
0.8182, NS 
FDAE vs PMMA-alginate FDAE total 0.0649, NS 
free 
0.0260, S 
alginate- FDAEvs PMMA-alginate-FDAE 
total 
0.1481, NS 
free 
0.0200, S 
 
 
The above-mentioned findings were supported by the permeability coefficient (Plumen) data 
shown in figure 5.6 and tables 5.3 and 5.4. The Plumen values were calculated based on the 
luminal disappearance of total and free luteolin using the Eqn. 1 at the steady-state period. The 
intestinal effective permeability represents a direct measurement of the local absorption rate and 
reflects the transport velocity across the epithelial barrier, expressed as centimeter per second 
(Lennernas, 1998). The Plumen values for intestinal uptake of total and free luteolin were higher 
from solutions of A. afra forms than the pure luteolin solution (i.e. Plumen values in the range of 
0.02 - 0.035 cm/s for all plant forms vs Plumenvalues in the range of 0.010 - 0.014 cm/s for pure 
luteolin, t-test p = 0.0252) confirming that the plant matrix form seemed to improve the intestinal 
disappearance of both the glycoside and aglycone forms of luteolin (Tables 5.3 and 5.4). This 
could be as a result of the uptake of luteolin glucoside and other luteolin derivatives in the 
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unhydrolysed form as opposed to the uptake of luteolin aglycone only in the hydrolysed 
form.These findings, thus confirm the suggestion made by Mukinda in his study, stipulating that 
plant matrix appeared to improve the intestinal disappearance of both the aglycone and glycoside 
forms of luteolin (Mukinda et al., 2010). It had been previously found in vervet monkeys that 
luteolin in the aqueous extract of A. afra had a significantly higher oral bioavailability than that 
of luteolin in a pure solution (Muganga, 2004).  
In addition, Mukinda et al., showed that luteolin in A. afra aqueous extract, regardless of its form 
(i.e. whether aglycone or glucoside), was better taken up and more efficiently metabolized than 
its aglycone and glucoside forms administered as pure solutions (Mukinda et al., 2010). This 
suggested that the plant matrix had an interesting effect on the uptake and subsequently 
metabolism of luteolin from A. afra.  
 
 
 
Figure 5.6: Permeability coefficients of A) total luteolin and B) free luteolin in pure luteolin and A. afra 
preparations across rat ileum. The rat intestine segment was perfused with 20 µg/ml pure luteolin, 
FDAE containing 5 µg/ml of luteolin, alginate-FDAE containing 2.5 µg/ml of luteolin and PMMA-
alginate-FDAE containing 2.3 µg/ml of luteolin.Plumen was calculated using Eq. 1, at the steady-
state (i.e. between 10 and 60 min). The histograms represent the mean values of three datasetsi.e. 
n=3. 
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The permeability of total and free luteolin in the FDAE appeared to be greater than that of the 
modified forms (Plumen>0.03 cm/s for FDAE and Plumen<0.03 cm/s for both modified forms), 
although the difference in uptake of luteolin (free and total) between FDAE and alginate-FDAE 
was statistically not significant (Table 5.5) whereas the difference in uptake of free luteolin 
between FDAE and PMMA-alginate-FDAE was statistically significant (p = 0.0260). The 
alginate-FDAE displayed greater uptake of luteolin (free and total) than the PMMA-alginate-
FDAE. The difference in uptake of total luteolin in these modified forms was statistically not 
significant (p = 0.0649) whereas that for free luteolin was statistically significant (p = 0.0260) 
(Table 5.5). 
Despite the fact that many studies have been done investigating the absorption of luteolin in 
either, the pure form or the plant form (Shimoi et al., 1998; Spencer et al., 1999), no studies have 
been conducted investigating the absorption of luteolin from different modified forms of the 
aqueous plant extract. Very little is known about the extent to which flavonoids are absorbed and 
the mechanisms of absorption involved. According to Chen et al, poor bioavailability of 
flavonoids results from their poor intrinsic permeation and transporter-mediated efflux (Chen et 
al., 2008). Liu et al, in their study, concluded that the low bioavailability of flavonoids is as a 
result of extensive phase II metabolism in the intestine (Liu and Hu, 2002). Song et al compared 
the permeability values among high, medium and low concentrations of metformin in the 
duodenal segment. A concentration-dependent change was observed, exhibiting a decrease in 
permeability at the highest drug concentration. The result suggested that intestinal absorption of 
metformin was via passive and transcellular mechanisms involving an active saturable process 
(Song et al., 2006). This could mean that the absorption sites in the ileum were saturated and 
hence the less of the pure luteolin was absorbed or disappeared, although it had a higher 
concentration (20 µg/ml) as compared to the amount of luteolin present in the plant forms (i.e. 
5µg/ml of luteolin in FDAE, 2.5 µg/ml of luteolin in alginate-FDAE and 2.3 µg/ml of luteolin in 
PMMA-alginate-FDAE).  Such a deduction will be in accordance with the results found in this 
study in which the amount of free and total luteolin disappearing frompure luteolin solution is 
lower than that of theA. afra plant forms as seen in figures 5.4 and 5.5. However, due to the very 
small amounts of luteolin identified and quantified in the in situ perfusate plant samples, special 
care should be paid to the loading of active herbal ingredient (AHI) into the plant preparation 
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when preparing plant dosage form formulations in order to maintain the effective blood 
concentration of AHI. 
 
With the experimental design, it was difficult to accurately compare the permeabilities of luteolin 
in pure form and A. afra plant forms due to the lack of mass balance done for all forms. This 
made it difficult to specifically ascertain which modified form showed better luteolin uptake. The 
mass of luteolin in the FDAE and beads was incomparable to the mass of luteolin (pure form) 
used in this study as seen from the luteolin concentrations in the perfusion solutions. To mitigate 
this problem, it was thus recommended that actives in plant forms be extracted and mass balance 
done for all forms to be investigated for future purposes. In addition it was not possible to 
determine whether the amount of luteolin will have any observable therapeutic effect in human. 
Thus further studies on the effect of these A. afra preparations in humans are required. 
 
5.4 Conclusion 
The results obtained from this study clearly suggested that luteolin present in the A. afra plant 
forms is absorbed into the circulation, although the exact mechanisms of absorption remain a 
subject of argument. The disappearance of luteolin was improved in the A. afra plant forms when 
compared to the pure luteolin solution with the FDAE showing slightly greater disappearance of 
luteolin that the modified forms.The total and free luteolin content in the perfusate samples of the 
alginate-FDAE and PMMA-alginate-FDAE beads indicated similar luteolin content disappearing 
from these beads. Collectively, these results indicate that the modified forms of the FDAE 
prepared i.e. alginate-FDAE and PMMA-alginate-FDAE beads should thus be suitable for use in 
the preparation of a solid dosage form e.g. tablet or capsule for Artemisia afra. 
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Chapter 6 
Conclusions and Recommendations 
The objectives of this study were; to prepare the freeze dried aqueous extract (FDAE) and its 
modified forms (alginate-FDAE and PMMA-Alginate-FDAE),to determine and compare the 
pharmaceutical characteristics of the various forms, to evaluate and compare the release 
characteristics of FDAE from the alginate-FDAE and PMMA-alginate-FDAE beads in simulated 
gastric fluid (SGF) and simulated intestinal fluid (SIF), and to determine the intestinal 
permeability of luteolin contained in the modified Artemisia afra extractpreparations. 
It was hypothesized that; making the modified forms of the FDAE of A. afra would make the 
FDAE less hygroscopic with a lower moisture content, the rate of release of luteolin from 
alginate-FDAE would be faster than that from PMMA-alginate-FDAE beads and finally that the 
effective gastrointestinal permeability (Peff) of luteolin in the alginate-FDAE and PMMA-
alginate-FDAE beads of A. afra FDAE would be equal to that in the FDAE. 
 
From the results obtained the following conclusions could be drawn; 
1. The yield of freeze dried aqueous material obtained from the aqueous extract of A. afra 
dried leaves was consistent with that obtained from other investigators.The modified 
preparations of A. afra also had organoleptic features, viz, colour, taste and odour which 
were identifiable and very distinctive. Unlike the FDAE whose colour changed from light 
brown to dark brown on storage in a desiccator at room temperature, the physical 
appearance of the modified forms (alginate-FDAE beads and PMMA-alginate-FDAE 
beads) was stable on storage without any visible physical changes. 
2. The moisture content of the modified forms of A. afra; alginate-FDAE beads and 
PMMA-alginate-FDAE beads were relatively low as compared to the FDAE. This result 
thus indicated improvement in counteracting the hygroscopicity of the FDAE and 
therefore improved storage over longer periods of time. 
3. A pH responsive release profile displayed by the alginate-FDAE and PMMA-alginate-
FDAE beads was observed, with faster release observed at a higher pH in SIF (6.8) 
compared to SGF (1.2) thus indicating slow release of flavonoids from the beads in the 
stomach and faster release in the intestine. 
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4. The FDAE contained higher levels of the marker luteolin than the modified forms which 
increased in all forms after hydrolysis. Relatively very small amounts of the marker 
compound luteolin were identified and quantified in the modified forms with PMMA-
alginate-FDAE having a higher percentage of conjugates than the two other forms. 
5. Luteolin was better taken up in the plant forms than in its pure form. The A. afra forms 
prepared had similar rates of uptake (permeability) of free and total luteolin with the rates 
being highest for the FDAE.  
 
In summary, the modified forms which include alginate-FDAE and PMMA-alginate-FDAE 
beads should be suitable for use in a solid dosage form (e.g. tablet or capsule) of A. afra. 
From the results, several areas for further research were noted. Firstly, there is a need to 
improve the entrapment efficiency of FDAE in alginate-FDAE and PMMA-alginate-FDAE 
beads. This will lead to an increase in the percentage of the FDAE (containing the actives) 
embedded in the beads. Secondly suitable excipients (e.g. Eudragit™) that can impact a non-
hygroscopic nature unto the herbal extract and in turn improve bioavailability of actives should 
be investigated to determine if the bioavailability of the A. afra flavonoids can be improved by 
preparing modified forms with comparable flavonoid chemical content (i.e. same Active Herbal 
Constituents (AHC) as the aqueous extract) but improved in vitro availability (i.e. dissolution) 
and intestinal uptake (i.e. trans-intestinal stability and permeability) characteristics. Lastly, 
further studies are required to indicate whether the permeability of luteolin as determined by the 
single pass intestinal perfused model also occur in vivo. A good marker which can be easily 
detected and quantified and a method of quantification for A. afra is needed. In addition to this, a 
study needs to be conducted with this marker on different batches of the various A. afra forms to 
give a broad and clear understanding of the absorption of luteolin in these forms and to further 
ascertain which of the forms is better. 
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Appendix 2 
Table showing the resultant yields obtained in the preparation of the freeze dried aqueous 
extract of Artemisia afra. 
Batch No Weight of the A. afra plant 
leaves (g) 
Volume of the water 
(L) 
Yield of the freeze dried 
aqueous extract (g) 
1 100 3.5 19.9 
2 100 3.5 21.6 
3 100 3.5 23.5 
Ave   21.733 
Std Dev   1.850 
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Appendix 3 
Particle size analysis of Artemisia afra preparations 
Artemisia afra plant preparation 
weight (g) 
Sieve No. Weight of 
powder 
passing 
through 
sieve (g) 
Weight of 
powder 
passed 
through as 
% of feed 
Fineness grading (BP 2000) 
A. afra dried leaves 355 2.2 21.8 Coarse powder 
180 0.47 4.7 
125 0.33 3.3 
90 0.24 1.2 
FDAE of A. Afra 355 5.9 59 Coarse powder 
180 2.87 28.7 
125 1.92 19.2 
90 0.89 8.9 
Alginate beads of A. Afra 1700 7.82 78.2 Not gradable 
1400 6.82 68.2 
1000 5.19 51.9 
500 5.15 51.5 
PMMA-alginate beads of A. Afra 1700 9.22 92.2 Not gradable 
1400 6.30 63 
1000 4.58 45.8 
500 4.52 45.2 
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Appendix 4 
Moisture content of Artemisia afra preparations 
Appendix 4.1: Table showing results of moisture content of FDAE of A. afra 
Sample No Initial weight of 
plant material(g) 
Final weight of dried 
plant material (g) 
Difference (g) Percentage of 
moisture 
1 0.3176 0.2861 0.0315 9.92 
2 0.3069 0.2739 0.033 10.75 
3 0.3087 0.2736 0.0351 11.37 
Ave 0.3110 0.2779 0.0332 10.68 
Std Dev 0.0057 0.0071 0.0018 0.7275 
 
Appendix 4.2: Table showing results of moisture content of alginate-FDAE beads of A. afra 
Sample No Initial weight of 
plant material(g) 
Final weight of dried 
plant material (g) 
Difference (g) Percentage of 
moisture 
1 0.3992 0.3724 0.0268 6.713 
2 0.3724 0.3466 0.0258 6.928 
3 0.3873 0.3616 0.0257 6.6357 
Ave 0.3863 0.3602 0.0261 6.7591 
Std Dev 0.0134 0.0129 0.0006 0.1514 
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Appendix 4.3: Table showing results of moisture content of PMMA-alginate-FDAE beads 
of A. afra 
Sample No Initial weight of 
plant material(g) 
Final weight of dried 
plant material (g) 
Difference (g) Percentage of 
moisture 
1 0.3339 0.3081 0.0258 7.7268 
2 0.3071 0.2817 0.0254 8.2709 
3 0.3221 0.296 0.0261 8.1030 
Ave 0.3210 0.2952 0.0257 8.0336 
Std Dev 0.0134 0.0132 0.0003 0.2786 
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Appendix 5 
Aqueous soluble fractionof preparations of A. afra 
Appendix 5.1: Table showing the aqueous soluble fractionof FDAE of A. afra 
Sample No Initial weight of plant 
material(mg) 
Weight of the 
residue on filter 
paper(mg) 
Weight of the soluble 
portion in the plant 
material (mg) 
Percentage of 
soluble material 
1 30.6 5.4 25.2 82.353 
2 30.2 5.1 25.1 83.113 
3 29.2 3.8 25.4 86.986 
4 32.5 5.3 27.2 83.692 
5 33.5 5.9 27.6 82.388 
6 28.6 4.4 24.2 84.615 
Ave 30.767 4.983 25.783 83.858 
SD ±1.896 ±0.757 ±1.324 ±1.753 
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Appendix 5.2: Table showing the aqueous soluble fractionof alginate-FDAE beads of A. 
afra 
Sample No Initial weight of 
plant material(mg) 
Weight of the 
residue on filter 
paper(mg) 
Weight of the soluble 
portion in the plant 
material (mg) 
Percentage of 
soluble material 
1 30.3 28.1 2.2 7.261 
2 29.7 27.4 2.3 7.744 
3 30.7 28.3 2.4 7.818 
4 31.2 28.7 2.5 8.013 
5 30.1 28.1 2 6.645 
6 29.4 27.2 2.2 7.494 
Ave 30.233 27.967 2.267 7.494 
SD ±0.656 ±0.565 ±0.175 ±0.492 
Appendix 5.3: Table showing the aqueous soluble fractionof PMMA-alginate-FDAE beads 
of A. afra 
Sample No Initial weight of 
plant material(mg) 
Weight of the 
residue on filter 
paper(mg) 
Weight of the soluble 
portion in the plant 
material (mg) 
Percentage of 
soluble material 
1 30.1 29.7 0.4 1.329 
2 30.4 30.2 0.2 0.658 
3 29.7 29.3 0.4 1.347 
4 29.6 29.5 0.1 0.338 
5 30.7 30.3 0.4 1.303 
6 30.3 30.1 0.2 0.660 
Ave 30.133 29.85 0.2833 0.939 
SD ±0.423 ±0.408 ±0.133 ±0.440 
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Appendix 6 
Entrapment efficiency of the FDAE in the alginate-FDAE beads and PMMA-alginate-
FDAE beads of A. afra 
Appendix 6.1: Table showing entrapment efficiency of the alginate-FDAE beads 
 Expected weight of 
extract per weight of 
beads 
Determined weight 
of extract per weight 
of beads 
Entrapment 
efficiency (%) 
Sample 1 0.3552 0.156 43.919 
Sample 2 0.3552 0.149 42.061 
Sample 3 0.3552 0.151 42.455 
Mean   42.812 
Standard deviation   0.979 
 
Appendix 6.2: Table showing entrapment efficiency of the PMMA-alginate-FDAE beads 
 Expected weight of 
extract per weight of 
beads 
Determined weight of 
extract per weight of 
beads 
Entrapment 
efficiency (%) 
Sample 1 0.3365 0.122 36.107 
Sample 2 0.3365 0.114 33.938 
Sample 3 0.3365 0.144 42.764 
Mean   37.603 
Standard deviation   4.599 
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Appendix 7 
Total flavonoid content 
Appendix 7.1: The absorbance readings at 349 nm of the hydrolysed and unhydrolysed 
preparations of A. afra 
Plant Sample hydrolysis Absorbance reading at 349nm in 
AUFs (Mean ± SD, n = 3) 
FDAE No 0.0907 ± 0.0012 
Yes 0.0988 ± 0.003 
Alginate- FDAE beads No 0.0756 ± 0.0013 
Yes 0.0771 ± 0.001 
PMMA-alginate-FDAE beads No 0.060 ± 0.001 
Yes 0.0623 ± 0.003 
Appendix 7.2: The total flavonoid content (μg of luteolin equivalents (LE) per 2.5 mg) of 
unhydrolysed and acid-hydrolysed plant material 
Plant Sample Hydrolysis Equivalent luteolin conc. in μg per 2.5 mg 
of plant sample (Mean ± SD, n = 3) 
FDAE No 49.762 ± 1.786 
Yes 61.333 ± 5.167 
Alginate- FDAE beads No 28.143 ± 1.789 
Yes 30.333 ± 1.929 
PMMA-alginate FDAE beads No 6.524 ± 1.668 
Yes 9.190 ± 3.786 
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Appendix 7.3: Comparison of the total flavonoid content expressed in μg of luteolin 
equivalents (LE) per mg for the unhydrolysed and acid-hydrolysed plant 
material 
Plant Sample Hydrolysis TFC (µg of LE/mg 
of extract) 
p value, (T-test result for 
unhydrolysed vs hydrolysed) 
FDAE No 19.905 0.0482; S 
Yes 24.533 
Alginate- FDAE beads No 11.257 0.2232; NS 
Yes 12.133 
PMMA-alginate FDAE 
beads 
No 2.609 0.3522; NS 
Yes 3.676 
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Appendix 8 
Appendix 8.1: Inter and intra day precision of HPLC asay for luteolin. Luteolin 
concentration is 4.3  µg/ml 
Assay day Measured luteolin concentration in sample (µg/ml) RSD(%) 
Time 1 Time 2 Time 3 Mean ± SD 
1 4.8591 4.8130 4.8716 4.848 ± 0.03 0.637 
2 4.7955 5.068 5.1105 4.991 ± 0.18 3.427 
3 4.8586 4.8409 4.8426 4.847 ± 0.01 0.201 
Inter-Day assay precision (RSD in 3 days) 4.895 ± 0.045 1.421 
 
Appendix 8.2: LOD and LOQ data for luteolin over the 4.5 – 27.0 µg/ml range at 350 nm 
Prepared 
concentration 
(µg/mL) 
Mean peak 
area 
(mAUFs) 
Concentration 
found 
(µg/mL) 
 
 
RSD (%) 
 
 
Bias
&
(%) 
 
 
LOD
#
 
 
 
LOQ 
8.7 775.59 8.47 0.25 -2.33 Accept Accept 
4.3 425.82 3.91 0.44 -9.74 Accept Accept 
2.17 269.15 1.87 5.10 -13.62 Accept Reject 
1.30 211.77 1.12 7.47 -13.49 Accept Reject 
0.43 -* -* -* -* Reject Reject 
&
Bias: The difference between the mean concentration measured and the prepared concentrations 
as a percentage of the prepared concentration. 
#
LOD: Determined using an analyte response 3 times that of the noise (signal-to-noise ratio of 
3:1) with the mean baseline noise = 0.4 a.u., n=3. 
*Concentration could not be determined since the peak area was less than the regression equation 
intercept. 
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Appendix 9 
Appendix 9.1: A representative HPLC chromatogram of unhydrolysed PMMA-alginate-
FDAE in situ perfusate sample at 30 min containing luteolin and phenol red. 
The retention time of luteolin is 13.8 while that for phenol red is 11.5. The 
chromatographic conditions are described in section 5.2.6. 
 
 
Appendix 9.2: A representative HPLC chromatogram of hydrolysed PMMA-alginate 
FDAE in situ perfusate sample at 30 min containing luteolin and phenol red. 
The retention time of luteolin is 13.8 while that for phenol red is 11.4. The 
chromatographic conditions are described in section 5.2.6. 
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Appendix 9.3: A representative HPLC chromatogram of unhydrolysed alginate-FDAE in 
situ perfusate sample at 30 min containing luteolin and phenol red. The 
retention time of luteolin is 13.8 while that for phenol red is 11.5. The 
chromatographic conditions are described in section 5.2.6. 
 
 
Appendix 9.4: A representative HPLC chromatogram of hydrolysed alginate-FDAE in situ 
perfusate sample at 30 min containing luteolin and phenol red. The 
retention time of luteolin is 13.8 while that for phenol red is 11.5. The 
chromatographic conditions are described in section 5.2.6. 
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Appendix 9.5: A representative HPLC chromatogram of unhydrolysed FDAE in situ 
perfusate sample at 30 min containing luteolin and phenol red. The 
retention time of luteolin is 13.8 while that for phenol red is 11.5. The 
chromatographic conditions are described in section 5.2.6. 
 
 
Appendix 9.6: A representative HPLC chromatogram of hydrolysed FDAE in situ 
perfusate sample at 30 min containing luteolin and phenol red. The 
retention time of luteolin is 13.8 while that for phenol red is 11.5. The 
chromatographic conditions are described in section 5.2.6. 
 
 
 
 
 
